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We reviewed 87 epidemiological studies relating environmental tobacco smoke (ETS) exposure to risk of
cancer other than lung or breast in never smoking adults. This updates a 2002 review which also
considered breast cancer. Meta-analysis showed no signiﬁcant relationship with ETS for nasopharynx
cancer, head and neck cancer, various digestive cancers (stomach, rectum, colorectal, liver, pancreas), or
cancers of endometrium, ovary, bladder and brain. For some cancers (including oesophagus, colon, gall
bladder and lymphoma) more limited data did not suggest a relationship. An increased cervix cancer risk
(RR 1.58, 95%CI 1.29e1.93, n ¼ 17 independent estimates), reducing to 1.29 (95%CI 1.01e1.65) after re-
striction to ﬁve estimates adjusting for HPV infection or sexual activity suggests a causal relationship, as
do associations with nasosinus cancer observed in 2002 (no new studies since), and less so kidney cancer
(RR 1.33, 95%CI 1.04e1.70, n ¼ 6). A weaker association with total cancer (RR 1.13, 95%CI 1.03e1.35,
n ¼ 19) based on heterogeneous data is inconclusive. Inadequate confounder control, recall bias, pub-
lication bias, and occasional reports of implausibly large RRs in individual studies contribute to our
conclusion that the epidemiological evidence does not convincingly demonstrate that ETS exposure
causes any of the cancers studied.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction1
In 2002, one of us (PNL) reviewed the evidence relating envi-
ronmental tobacco smoke (ETS) exposure to risk of cancer of sites
other than the lung in never smoking adults (Lee, 2002). That re-
view, based on 38 studies, concluded that the epidemiological ev-
idence then available provided little support for the view that ETS
causes cancer at any of the sites considered. However, it did note
that three small, relatively weak, studies all reported a statistically
signiﬁcant association of ETS with nasosinus cancer. Since that re-
view, the literature has expanded considerably, and it seems
appropriate to carry out an updated review. As the literature on
breast cancer is now so substantial, we consider this separately (Lee
and Hamling, 2016, submitted for publication), restricting ourselves
here to the other cancers considered previously. As before,ETS, environmental tobacco
eplacement therapy; OC, oral
y drug; RR, Relative risk.
Inc. This is an open access article uattention is restricted to never smokers because many of the can-
cers are associated with active smoking, and reliable detection of
any effect of ETS exposure on a smoking-associated disease in the
presence of a history of smoking is extremely difﬁcult (Lee, 1992).
Our review also compares and contrasts our conclusions with
those of what wewill term “authoritative reviews” of health effects
of ETS published since our earlier review (California Environmental
Protection Agency, 2005; International Agency for Research on
Cancer, 2004, 2012; US Surgeon General, 2006) as well as with
those of other published reviews relating to speciﬁc cancers.
Before discussing the evidence from the individual studies in
detail, it is important to be aware of a number of issues that are
generally relevant. These were discussed in more detail earlier (Lee,
2002) and are only outlined below.1.1. Confounding
Since ETS exposure is associated with dietary and other lifestyle
factors associated with adverse health (Dallongeville et al., 1998;
Forastiere et al., 2000; Iribarren et al., 2001; Thornton et al.,
1994) it is important that studies adequately adjust for thesender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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incidence of a cancer is seen.
1.2. Misclassiﬁcation bias
The tendency for some current or former smokers to deny
having smoked, coupled with the tendency of spouses to have
similar smoking habits, is known to bias upward the relationship of
spousal smoking to lung cancer (Fry and Lee, 2001; Hackshaw et al.,
1997; Lee et al., 2016). The same bias may be relevant for other
cancers strongly associated with active smoking.
1.3. Publication bias
Researchers may be less likely to publish, and editors less likely
to accept for publication, studies showing no statistically signiﬁcant
association between exposure and disease (Sutton et al., 2000;
Thornton and Lee, 2000). This may lead to the published evi-
dence overestimating any true associations. Large cohort studies
fromwhich results for only some cancer types have been published
strongly suggest the possibility of publication bias.
1.4. Diagnostic inaccuracy
Clinical diagnosis of cancers is subject to substantial errors
(Burton et al., 1998; Szende et al., 1996) and such misdiagnosis may
bias estimated RRs in either direction.
1.5. Errors in determining ETS exposure
While random errors in determining ETS exposure will under-
estimate a true relationship, recall bias, a perennial problem in
case-control studies, may lead to overestimation. Objective mea-
sures of exposure based on biomarkers such as cotinine avoid the
issue of recall bias, but are rarely used.
1.6. Reference group
Some case-control studies ask detailed questions about multiple
sources of ETS exposure during the subject’s lifetime, and use those
with no reported exposure at all as the reference group. Since
everyone is likely to have had some ETS exposure in their life, RR
estimates are highly dependent on which subjects get included in
the reference group, and may be unusually subject to recall bias.
Estimates based on whether or not the subject is married to, or
work with, a smoker may be more reliable.
1.7. Plausibility
Since exposure to tobacco smoke constituents from ETS is much
less than that from active smoking, with studies based on cotinine
indicating relative exposure factors of less than 0.5% (Benowitz
et al., 2009; Ofﬁce of Population Censuses and Surveys (1996);
Pirkle et al., 1996) and studies on particulate matter a lower factor
still (e.g. Phillips et al., 1998a; b; Phillips et al., 1994), it seems
implausible that ETS might increase risk of cancers not associated
with active smoking, or produce increases in risk similar to those
seen for smoking.
2. Materials and methods
Attention is restricted to epidemiological prospective, case-
control or cross-sectional studies published up to and including
November 2015, which involve ﬁve or more cancers of any of the
speciﬁc types considered, and which provide relative risk (RR)estimates for never (or virtually never) smokers for one or more
deﬁned ETS exposure types or dose-related ETS indices. RRs
generally compare subjects exposed and unexposed to ETS from
various different sources including spouse, household, workplace,
childhood, travel, social and total, the ﬁnal category including
biochemical assessments of exposure. Note that the term “relative
risk” is taken to include estimates of it, such as the odds ratio or
hazard ratio. Studies using near equivalent deﬁnitions of “never
smokers” are accepted when similar deﬁnitions are unavailable, so
never smokers could include occasional smokers, those with a
minimal duration of smoking or number smoked, or long-term ex-
smokers.
Up until November 2015, potentially relevant papers were
regularly sought from MedLine searches restricted to humans and
using the search terms “(passive smoking OR environmental to-
bacco smoke OR involuntary smoking) AND cancer”, from ﬁles on
smoking and health which were collected for many years within
our company, and from references cited in the papers obtained and
in other reviews.
For each cancer and exposure index, RRs and 95% conﬁdence
intervals (CIs) were extracted/which were adjusted for the most
potential confounding factors. Where necessary, these estimates
were derived by combining independent RRs by ﬁxed effect meta-
analysis (Fleiss and Gross, 1991), or by combining non-independent
RRs, e.g. for different exposure levelswith the same reference group
(Hamling et al., 2008).
Where four or more studies provided independent estimates of
risk, random effectsmeta-analysis (Fleiss and Gross,1991)was used
to derive an overall RR estimate with CI, and a test of publication
bias (Egger et al., 1997) was conducted. Where a study provides
multiple estimates for a given sex, only one estimate was used in
the main meta-analysis, preference being given to estimates for
adult rather than for childhood exposure, and to estimates for
spousal exposure or exposure to a cohabitant rather than for
workplace, social or total exposure. For each cancer type, further
meta-analyses for prospective and non-prospective studies sepa-
rately were carried out whenever four or more of the analysed
studies were of prospective design and four or more were of non-
prospective design. For some cancers, for reasons discussed in the
results section, some meta-analyses were rerun omitting estimates
from speciﬁc studies.
Where data permitted, additional meta-analyses were con-
ducted based on more speciﬁc exposure deﬁnitions; at home, at
work, in childhood or total. Where multiple estimates were avail-
able for a study, preference was given to the estimate for the widest
deﬁnition of exposure (e.g. any cohabitant rather than spouse for at
home exposure) and to the estimate likely to be the most relevant
(e.g. mother rather than father for childhood exposure, where an
estimate relating to overall childhood exposure was not available).
A deﬁnition of total exposure had to include exposure both inside
and outside the home.
3. Results
3.1. Appendix tables
Details of each study and the meta-analyses are given in Ap-
pendix Tables. Following a summary of relevant characteristics for
each study in Appendix Table 1, results are presented in Appendix
Tables 2e12 for the following 11 cancer groupings: head and neck;
digestive system; cervix; endometrium; ovary; kidney; bladder;
brain; lymphoma; other sites and total cancer incidence. For each
study providing data, results are presented (by sex if possible)
relating to various ETS exposure indices. For each study/sex/index,
the tables show the source and timing of the exposure, the number
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footnote, the reference group comprises subjects unexposed to the
speciﬁed ETS exposure source. The tables also show whether dose-
response was studied and, if so, whether the trend was statistically
signiﬁcant (p < 0.05), with fuller details of signiﬁcant trends given
in the footnotes. The footnotes also list studies excluded as their
analyses were not restricted to never smokers. The tables also
indicate whether age and other potential confounding variables
have been taken into account, as well as other details of the anal-
ysis, including whether the RRs and CIs had to be estimated from
results provided in a different format.
Results of the main random-effects meta-analysis (giving pref-
erence to estimates for adult exposure from a spouse or cohabitant)
are shown in Appendix Tables 2e12. The footnotes to the Appendix
Tables give details of tests for heterogeneity, for differences by
study type, and for publication bias.
Results shown in Appendix Tables 2e12 are usually given for all
the indices of ETS exposure reported. Exceptionally, where studies
reported results for a very wide range of sources of ETS exposure,
only results for those most often considered generally (spouse, co-
worker, cohabitant, parent during childhood) are presented.
3.2. Figures
Results of the meta-analyses and some details of the studies
included in them are given in Figures as forest plots. The results of
various sensitivity analyses are included. Within each Figure, pro-
spective studies are marked *. Each result is presented as a square
centred at the RR value and a horizontal line representing thewidth
of the conﬁdence interval. This width is shown on a logarithmic
scale.Where the linewould run over the text to right or left, the line
is terminated at the edge of the text and an arrowhead is shown at
the terminated end. Within each Figure the area of each square is
approximately proportional to the meta-analysis weight of the
result (the inverse of its variance), scaled to give adequate square
size. The size of the squares can therefore be compared within each
Figure but not between Figures. The square for a sensitivity analysis
(labelled “Total”) is shownwhite with a black margin and an overall
meta-analysis result (labelled “Overall”) is represented as a white
square with a black cross, these being scaled as for the individual
study results.
3.3. Studies included
Details of each study providing relevant data are given in
Appendix Table 1. Compared with our earlier review (Lee, 2002),
which considered 38 studies, nine of which provided results only
for breast cancer, 87 studies are now included. Of these, 10 reported
results in the 1980s, 17 in the 1990s, 43 in 2000e2009, and 17 since
2010. Forty-three studies were carried out in North America, 22 in
Asia, 14 in Europe and three in Australasia. Two studies took place
in Egypt, one in South America, and two in multiple continents.
Sixty studies were of case-control design, while 25 were pro-
spective cohort studies. The remaining two studies were cross-
sectional. Seventy-six studies presented results for a single
endpoint, while 12 others considered two or more endpoints, four
of these investigating 10 or more cancer sites.
Nine studies did not adjust their results for any potentially
confounding variables, while two carried out adjustment but did
not specify the variables used to do this. Of the 76 remaining
studies, only three did not adjust for age, and all but three studies
either carried out adjustment for sex, or presented results
restricted to a single sex. Of the wide range of other adjustment
factors considered in the studies, race, area of residence/, education,
body mass index, dietary factors and alcohol consumption weremost frequently considered. Quite a number of estimates were
adjusted for relatively few potential confounding variables.
3.4. Head and neck cancers
Appendix Table 2 gives results from ﬁve studies for cancer of the
nasopharynx, from three for nasal sinus cancer, and from nine for
head and neck cancer.
3.4.1. Nasopharynx cancer
See Fig. 1. The ﬁve studies were all considered in our earlier
review (Lee, 2002). While Armstrong et al. (2000) reported a sig-
niﬁcant relationship with childhood but not adulthood ETS expo-
sure, and Yuan et al. (2000) reported signiﬁcant increases with
various exposure indices in males, but not females, the other three
studies provided no evidence of an increase in risk associated with
ETS exposure. Meta-analysis, based on ﬁve estimates from four
studies (see Fig.1) gave an overall estimate of 1.40 (0.71e2.76), with
evidence of heterogeneity (p ¼ 0.0017).
Given the heterogeneous ﬁndings, the fact that all the studies
were of case-control design, and the limited control for potential
confounding variables, the overall ﬁndings must be regarded as
inconclusive, a conclusion in agreement with various authorities
(California Environmental Protection Agency, 2005; International
Agency for Research on Cancer, 2004; US Surgeon General, 2006).
3.4.2. Nasosinus cancer
Again, the studies were all considered earlier (Lee, 2002). The
three studies of this rare cancer provided some evidence of an as-
sociationwith ETS exposure, with all the RRs>1 and onemarginally
signiﬁcant. However, the small number of cases, the very limited
control for potential confounding variables and, in the study
reporting the largest RRs (Zheng et al., 1993), the reliance on data
collected from next-of-kin, means that the ﬁndings cannot be
regarded as conclusive. Though some authorities (International
Agency for Research on Cancer, 2004; US Surgeon General, 2006)
also regard this evidence as inadequate, other reviewers
(Benninger, 1999; California Environmental Protection Agency,
2005; Doll, 1996; Jinot and Bayard, 1996) consider it at least
strongly suggestive of a causal relationship.
3.4.3. Cancers of the head and neck
See Fig. 2. Of the nine studies reporting results for cancer of the
head and neck, three were considered earlier (Lee, 2002). Two
studies (Chuang et al., 2011; Lee et al., 2009) were based on the
same participants, and although some overlap may exist between
the categories “ever exposed at home” and “ever exposed during
childhood”, this was considered minimal, so both studies were
included. Six studies (Chuang et al., 2011; Hirayama,1987; Lee et al.,
2008; Ramroth et al., 2008; Stingone et al., 2013; Zhang et al., 2000)
reported no signiﬁcant association of ETS exposure with risk,
although one (Lee et al., 2008) did ﬁnd a signiﬁcantly positive dose-
response relationship in subjects exposed to ETS at home only. One
study (Tan et al., 1997), which was based on unadjusted analyses
and collected data very differently for cases and controls, reported
signiﬁcantly increased risks with ETS exposure from the spouse and
at work. Another study (Troy et al., 2013) reported a signiﬁcantly
increased risk associated with exposure during childhood to sib-
lings who smoked, but not to any other source of ETS exposure in
childhood, and also reported a signiﬁcantly positive dose-response
relationship for those ever exposed in childhood as measured by
the number of smokers in the household, but not with cigarettes
per day or pack-years of exposure. The ﬁnal study (Lee et al., 2009)
found an increase in the risk of cancer of the oral cavity and
oropharynx, but not of the larynx and hypopharynx, for subjects
Fig. 1. Results from studies of nasopharynx cancer.
Fig. 2. Results from studies of cancers of the head and neck.
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response relationships, based on categories of years of exposure,
were also found for this endpoint for this source of exposure, and
for subjects who were exposed at work only.
Meta-analysis, based on 10 RR estimates, gave an overall risk of
1.20 (95% CI 0.95e1.52) using a random effects model. Although the
heterogeneity is not signiﬁcant (p ¼ 0.10), the overall estimate is
affected by the unusually high RR of 7.34 for females in one study
(Tan et al., 1997). Removing the RRs for this study removes the
heterogeneity, the overall estimate reducing to 1.11 (95% CI
0.95e1.29). The overall results do not suggest that ETS exposure
increases the risk of head and neck cancers; a view consistent with
other published reviews (e.g. International Agency for Research on
Cancer, 2004).3.5. Cancers of the digestive system
Whereas our earlier review (Lee, 2002) presented results from
only four studies, the results shown in Appendix Table 3 are based
on over 20, a number of which provide data for more than one of
the eight sub-groupings considered.3.5.1. Cancer of the oesophagus
Four studies considered oesophagus cancer. One study in China
(You et al., 2003) showed a marginally signiﬁcantly raised RR, and
reported the existence of a positive dose-response relationship.
However, no signiﬁcant RRs or trends were reported in the other
studies, with four of the ﬁve RRs presented below 1.00.3.5.2. Stomach cancer
See Fig. 3. Seven studies examined the risk of stomach cancer.
None of the nine RRs shown in Appendix Table 3 are statistically
signiﬁcant, with four estimates above 1 and ﬁve below 1.
The lack of association is also evident in the meta-analysis
where, based on seven RRs, the combined estimate is 1.02 (95% CI
0.91e1.14). Available data on dose-related trends do not provide
strong evidence of a true relationship, with You et al. (2003)
reporting a dose-relationship with total years of ETS exposure
(signiﬁcance not stated) and Chuang et al. (2011) reporting a
negative trend of borderline signiﬁcance (p ¼ 0.05) for cancers of
the stomach and cardia combined. Also, while Mao et al. (2002)
reported a signiﬁcant (p ¼ 0.03) positive trend for cancers in the
cardia subsite and no indication of an association for the distal
Fig. 3. Results from studies of stomach cancer.
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response for cardia cancers and a signiﬁcant (p ¼ 0.03) positive
trend for distal cancers.3.5.3. Colon cancer
One study (Sandler et al., 1988) implausibly reported a signiﬁ-
cant positive association with ETS exposure in males and a signif-
icant negative association in females. Other studies showed no
indication of a relationship.3.5.4. Rectal cancer
See Fig. 4. For rectal cancer, six of the seven RRs presented were
above 1.00, although only one (Hooker et al., 2008) was signiﬁ-
cantly so. This RR (5.81, 95% CI 1.84e18.36) for males in the 1963
cohort, was considerably higher than seen in other studies, and
may be considered an outlying result given that the other RRs from
this study (for females in the 1963 cohort, and for both sexes in the
1975 cohort) were only marginally above 1.00, and also given the
weakness of the association between active smoking and digestive
cancers. The meta-analysis RR of 1.36 (95% CI of 0.81e2.26), based
on six estimates, does not provide clear evidence of an effect of ETS
exposure.Fig. 4. Results from stud3.5.5. Colorectal cancer
See Fig. 5. Of the 15 RR estimates, seven are greater than 1.0 and
eight less than 1.0. The only signiﬁcant RR (Verla-Tebit et al., 2009)
is a negative relationship with childhood exposure for males, fe-
males with the same exposure showing a non-signiﬁcant positive
relationship. Based on seven RRs, meta-analysis gave a combined
estimate of 1.06 (95% CI 0.88e1.29) which was also not signiﬁcant.
Although Peppone et al. (2010) reported a signiﬁcant positive trend
with increasing hours/exposure, no other signiﬁcant trends were
seen, and the overall evidence must be reported as not indicative of
any true effect of ETS exposure.3.5.6. Liver and gall bladder cancer
Five studies presented results. For liver cancer, see Fig. 6, Hassan
et al. (2008) reported RRs consistently below 1.0, (with two of these
estimates statistically signiﬁcant). However, except for a positive
trend with years of ETS exposure noted by You et al. (2003), the
other studies reporting data for liver cancer showed no real evi-
dence of a relationship with ETS exposure, as conﬁrmed by a meta-
analysis based on ﬁve RRs, which gave a combined estimate of 0.84
(0.63e1.12).
Results for gallbladder cancer were very limited, providing no
evidence of an association with ETS exposure.ies of rectal cancer.
Fig. 5. Results from studies of colorectal cancer.
Fig. 6. Results from studies of liver cancer.
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See Fig. 7. Eleven studies investigated the association between
ETS exposure and pancreatic cancer. Nine studies reported no
signiﬁcantly increased or decreased RRs or trends, but two studies
reported substantially increased RRs. Thus a study in Egypt (Lo
et al., 2007) reported a signiﬁcant six-fold rise in risk associated
with ETS exposure from a cohabitant, while another study, based
on 10 European countries (Vrieling et al., 2010 reporting the
Chuang et al., 2011 study) reported a signiﬁcant nearly four-fold
increase associated with lifetime ETS exposure. That study also
reported a signiﬁcant trend in risk with increasing childhood ETS
exposure and a marginally signiﬁcantly increased RR with ETS
exposure at home or work. Based on 12 independent RRs, the
random-effects estimate was a non-signiﬁcant 1.16 (95% CI
0.92e1.47). Sensitivity analyses, by study type, showed non-
signiﬁcant increases for both prospective and case control
studies. Removing the estimate from the study in Egypt (Lo et al.,
2007) on the basis that it contributed largely to the overall het-
erogeneity of the data, the overall estimate reduced to 1.09 (95% CI
0.94e1.28) with insigniﬁcant remaining heterogeneity.3.5.8. All digestive cancers
Only two studies considered cancers of the digestive system
combined. While one study failed to ﬁnd any association, the other
(Miller, 1990) reported a 10.8-fold increase in risk for all digestive
cancers, a result which is totally inconsistent with the ﬁndings for
individual cancers within the digestive system.Overall, there is no compelling evidence that ETS exposure is
associated with digestive cancer, either for individual sites or for all
digestive cancers combined. This conclusion is consistent with the
authoritative reviews (California Environmental Protection Agency,
2005; International Agency for Research on Cancer, 2004, 2012; US
Surgeon General, 2006).3.6. Cervix cancer
Although it has been concluded that smoking is a cause of cervix
cancer (International Agency for Research on Cancer, 2004; US
Surgeon General, 2004), interpretation of the evidence is made
more difﬁcult by the major role of sexual activity, and in particular
exposure to human papillomavirus (HPV) infection, in the aetiology
of the cancer (Doll, 1996; Szarewski and Cuzick, 1998).
Of the 17 studies reporting results relating ETS exposure to risk
of cervix cancer (or in some cases endpoints that also included, or
were restricted to, pre-invasive cervical lesions) (see Fig. 8 and
Appendix Table 4), eight were published since our earlier review
(Lee, 2002). Only one estimate (Tsai et al., 2007) was adjusted for
HPV infection, and only ﬁve studies (Coker et al., 1992; Louie et al.,
2011; Scholes et al., 1999; Slattery et al., 1989; Tsai et al., 2007)
adjusted for aspects of sexual activity linked to HPV infection. Three
of these ﬁve studies (Coker et al., 1992; Louie et al., 2011; Tsai et al.,
2007) also adjusted for screening for cervical cancer. In these ﬁve
studies, the only statistically signiﬁcant RRs were a negative rela-
tionship with parental smoking in one US study (Coker et al., 1992)
Fig. 7. Results from studies of pancreatic cancer.
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(Scholes et al., 1999), though signiﬁcant increasing dose-response
relationships were noted with extent of daily ETS exposure
(Slattery et al., 1989) and with pack-years of ETS exposure (Tsai
et al., 2007).
Among the other studies, seven reported signiﬁcantly increased
RRs, sometimes also reporting signiﬁcant positive dose-related
trends. Two of these studies were conducted in the USA (Sandler
et al., 1985a; Trimble et al., 2005), one in Japan (Hirose et al.,
1996), one in Taiwan (Wu et al., 2003) and three in India (Abbas
et al., 2014; Kordi Tamandani et al., 2008 and Shekari et al., 2012;
Sobti et al., 2006). This contrasted with no reports of negative
relationships.
While a random-effects meta-analysis based on 17 independent
estimates shows a signiﬁcant elevation in risk (RR 1.58, 95% CI
1.29e1.93), there is evidence of heterogeneity (p ¼ 0.001), mainly
due to the high RR of 5.13 (95% CI 2.54e10.4) in the ﬁrst study in
India (Sobti et al., 2006). However, excluding this study still left the
combined estimate signiﬁcantly elevated (RR 1.48, 95% CI
1.24e1.76). The combined estimate reduced, but remained signiﬁ-
cant (RR 1.29, 95% CI 1.01e1.65) if the analysis was restricted to
those ﬁve studies that adjusted for sexual activity and/or for HPV
infection (marked y in Fig. 8). Analyses by study type gave a non-
signiﬁcantly raised estimate for prospective studies and a higher,
signiﬁcantly raised estimate for case control and cross-sectional
studies (which included Sobti et al., 2006).
While the results may seem indicative of an effect of ETS on
cervix cancer, there are considerable limitations in the available
data. Thus one of the studies in India (Sobti et al., 2006) and the
study in North Carolina (Sandler et al., 1985a, 1985b), both of which
reported signiﬁcant associations with ETS exposure, did not evenadjust for age, and in the case of the North Carolina study may have
compared female cases with a mixture of male and female controls.
Control for potential confounding variables was also very limited in
three of the studies reporting signiﬁcant associations (Abbas et al.,
2014; Hirose et al., 1996; Kordi Tamandani et al., 2008 and Shekari
et al., 2012) and in three that did not (Butler, 1988; Hirayama, 1987;
Nishino et al., 2001). Although some studies adjusted for a wider
range of variables, two reporting signiﬁcant associations (Trimble
et al., 2005; Wu et al., 2003) and two not (Chuang et al., 2011; Jee
et al., 1999), none of them adjusted for HPV infection or aspects
of sexual activity.
Other problems are clearly evident in some studies. The study in
Japan (Hirose et al., 1996) used cancer-free patients as controls, not
excluding those with smoking-related diseases. The study that
provided most weight to our ﬁnal meta-analysis based on ﬁve es-
timates (Scholes et al., 1999) recorded data on recent ETS exposure,
and concerned low-grade cervical abnormalities and not cancer. It
is also notable that none of the other seven studies for which
signiﬁcantly increased RRs were reported adjusted for HPV infec-
tion or aspects of sexual activity, though two studies that reported a
signiﬁcantly increased trend (Slattery et al., 1989; Tsai et al., 2007)
did so adjust. The question arises as to how well such adjustment
can eliminate the confounding effect. As noted earlier (Lee, 2002),
the study in Utah (Slattery et al., 1989) reported huge unadjusted
RRs for active smoking (10.1 for current smokers) and ETS exposure
(14.8 for 3 or more hours per day) which were massively reduced
(to 3.4 and 3.0, respectively) after adjustment only for number of
sexual partners, a limited adjustment which leaves open the pos-
sibility of residual confounding.
About 10 years ago, two authoritative reports (International
Agency for Research on Cancer, 2004; US Surgeon General, 2006)
Fig. 8. Results from studies of cervix cancer.
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inadequate to reach a conclusion, while another (California
Environmental Protection Agency, 2005) considered that expo-
sure to ETS “may increase the risk”, an opinion consistent with a
later review (Pate Capps et al., 2009) which only referred to a few of
the available studies. A much more recent report by IARC
(International Agency for Research on Cancer, 2012) referred to
most of the studies considered in Fig. 8 and Appendix Table 4, but
concluded that the “data are conﬂicting and sparse” for the asso-
ciation with ETS exposure, and did not include cancer of the cervix
among the cancers for which there is “sufﬁcient evidence” of car-
cinogenicity. While use of the word “sparse” is somewhat surpris-
ing given the relatively large number of studies, we do agree that
the available data are not conclusive. However, we would regard
the data as suggestive of a causal relationship.
3.7. Endometrial cancer
Results from the ﬁve studies are given in Fig. 9 and Appendix
Table 5. Only one of these studies had been considered earlier
(Lee, 2002). Chuang et al. (2011) found a signiﬁcantly decreased risk
in subjects exposed to ETS during childhood, but no evidence of a
dose-response relationship. No other study reported a signiﬁcantassociation or trend. Meta-analysis of the six available results gave
an overall RR estimate of 0.88 (95%CI 0.78e1.01). Thus, there is no
clear association between risk of endometrial cancer and ETS
exposure.
3.8. Cancer of the ovary
Results from six studies, only one considered earlier (Lee, 2002),
are given in Fig. 10 and Appendix Table 6. Baker et al. (2006) re-
ported a signiﬁcant reduction in risk and negative dose-related
trend with total ETS exposure. The remaining ﬁve studies failed
to ﬁnd any association between ovarian cancer incidence and ETS
exposure. The meta-analysis RR of 0.91 (95%CI 0.76e1.09) does not
suggest any increase in risk of ovarian cancer related to ETS
exposure.
3.9. Cancer of the kidney
Fig. 11 and Appendix Table 7 give results from four studies, one
considered earlier (Lee, 2002). Eight of the nine RRs presented are
above 1.00, with that for home or work exposure from Theis et al.
(2008) being statistically signiﬁcant, and another two RRs, from
Hu et al. (2005), just failing to be. Signiﬁcant dose-related trends
Fig. 9. Results from studies of endometrial cancer.
Fig. 10. Results from studies of cancer of the ovary.
Fig. 11. Results from studies of cancer of the kidney.
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marginally signiﬁcant positive trend in females for hours per day
of ETS exposure at home or work. However, this was based on a
dose-relationship pattern that was actually quite erratic. Hu et al.
(2005) showed a non-signiﬁcant trend with years of exposure for
females but a signiﬁcant positive trend for males. Theis et al.
(2008) showed positive trends for some of the measures of ETS
exposure considered, although only the relationship betweenexposure at home and/work showed a clear increase in risk with
increasing exposure.
Based on six estimates, meta-analysis gives a combined RR of
1.33 (95% CI 1.04e1.70) with no evidence of heterogeneity. While
suggestive of a relationship, the limited number of studies and the
lack of a signiﬁcant increase in risk in the only prospective study
(Chuang et al., 2011) indicate that more evidence is required before
any ﬁrm conclusion can be reached. This conclusion is consistent
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Agency for Research on Cancer, 2012).3.10. Bladder cancer
Cigarette smoking is a well-established risk factor for bladder
cancer (International Agency for Research on Cancer, 2004; US
Surgeon General, 2004). The relationship of ETS exposure to
bladder cancer has been investigated by 15 studies (Fig. 12 and
Appendix Table 8), only three considered earlier (Lee, 2002). Nine
studies (Baris et al., 2009; Bjerregaard et al., 2006; Burch et al.,
1989; Chuang et al., 2011; Ferreccio et al., 2013; Hirayama, 1987;
Kabat et al., 1986; Zeegers et al., 2002; Zheng et al., 2012) re-
ported no signiﬁcant association between bladder cancer risk and
any index of ETS exposure, but some evidence of an associationwas
seen in the other six studies.
Chen et al. (2005) reported a signiﬁcant increase in men but not
women, based on extremely few cases. Samanic et al. (2006) re-
ported a signiﬁcant increase in risk and dose-related trend in
women with workplace exposure, but not other exposures, butFig. 12. Results from studwith no index of exposure in men. Alberg et al. (2007) reported a
signiﬁcant increase for one of three indices of exposure (co-
habitants other than the spouse) in the 1963 cohort, but not for any
index in the 1975 cohort. Jiang et al. (2007) reported signiﬁcant
dose-related trends with childhood and total exposure in women,
but no signiﬁcant results for other exposures in women, or for any
exposure in men. Tao et al. (2010) reported a positive dose-
response relationship for childhood ETS exposure in women, but
no signiﬁcant relationships for men or for other exposures in
women. In Wu et al. (2013), a signiﬁcantly increased RR could be
estimated for exposure to ETS from any source. However, due to
lack of information on numbers of cases and controls by ETS
exposure this estimate was based on an approximate calculation
and may be somewhat unreliable.
A random-effects meta-analysis based on 22 independent esti-
mates gave a risk estimate of 1.13 (95% CI 0.98e1.30), with no ev-
idence of heterogeneity. Results by study type gave similar non-
signiﬁcant results for both prospective and case control studies.
Overall, then, no clear increase in risk has been demonstrated.
While earlier reviews (California Environmental Protectionies of bladder cancer.
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US Surgeon General, 2006; Zeegers et al., 2004) considered the
evidence inadequate to reach a conclusion, only a few of the studies
included in Fig. 12 and Appendix Table 8 could have been included.
Althoughmore recent reviews have been published (Boffetta, 2008;
International Agency for Research on Cancer, 2012; Letasiova et al.,
2012), they still refer to the limited nature of the data, and none
consider any effect of ETS established, consistent with our own
conclusions.
3.11. Brain cancer
Although it has been suggested (Hurley et al., 1996) that ciga-
rette smoking may cause brain cancer, due to the presence of
various N-nitroso compounds in tobacco smoke, epidemiological
studies have generally not suggested an association (Fan et al.,
2013; International Agency for Research on Cancer, 2004). Results
from the eight studies on ETS exposure, six considered earlier (Lee,
2002), are given in Fig. 13 and Appendix Table 9. Three relate to
overall brain cancer, two to glioma, one to meningioma, one to
cancers of the brain and nervous system, and one to glioma and
meningioma combined (see Appendix Table 1). Of the 14 RRs pre-
sented, eight are increased, but in only one study (Phillips et al.,
2005) is the risk statistically signiﬁcant. This result related to
exposure from the spouse, with no increase seen for ETS from other
cohabitants or co-workers. This study, which also found a signiﬁ-
cant positive trend for years of exposure to spousal ETS, reported a
signiﬁcant positive association with active smoking for men but a
signiﬁcant negative association with active smoking for women.
Three other studies (Chuang et al., 2011; Hirayama, 1985; Johnson
et al., 1999) also reported a signiﬁcantly positive dose-related
trend in risk with increasing ETS exposure. However, Hirayama
(1985) did not adjust for the age of the subject, Johnson et al.
(1999) only reported their results in an abstract with little detail,
while RRs reported by Chuang et al. (2011) did not show a clear
trend of increasing risk with increasing exposure. Few potential
confounding variables have been adjusted for in any of the studies.
Meta-analysis based on 10 independent estimates gave a RR
estimate of 1.25 (95% CI 0.97e1.60). Our conclusion that there is no
clear evidence for an increase in brain cancer incidence fromFig. 13. Results from stuexposure to ETS is consistent with that of other reviews (California
Environmental Protection Agency, 2005; International Agency for
Research on Cancer, 2004, 2012; US Surgeon General, 2006).
3.12. Lymphoma
Results from four studies, one considered earlier (Lee, 2002)
are given in Appendix Table 10. In three studies, there was no
evidence of an increased risk or dose-response associated with
ETS exposure. While in the other (Lu et al., 2011) the four RRs
shown were all non-signiﬁcantly raised, signiﬁcantly increased
trends were noted for various measures of total ETS exposure.
Overall, the data provide little convincing evidence that exposure
to ETS increases the risk of lymphoma, a conclusion consistent
with that of authoritative reviews (e.g. International Agency for
Research on Cancer, 2012).
3.13. Cancer of other sites
Appendix Table 11 summarizes the limited results that are
available for eight cancer sites (or groups of sites) not presented
above. Most of these data are relatively old and were considered
earlier (Lee, 2002).
For ﬁve sites (bone, skin, female genital, thyroid, and all hae-
matopoietic), no signiﬁcant associations or trends were reported,
with results only available for one or two studies.
For endocrine cancer, Sandler et al. (1985a) reported a signiﬁ-
cant associationwith spousal smoking. However, this was based on
only 13 cases, and was unstandardized for either age or sex.
Weaknesses of this study have been discussed earlier (Lee, 2002).
No signiﬁcant association was seen with childhood ETS exposure
(Sandler et al., 1985b).
For prostate cancer, the only study reporting ﬁndings (Chuang
et al., 2011), showed a marginally signiﬁcant negative association
with childhood ETS exposure.
For leukaemia, no signiﬁcant trend was noted in the Japanese
prospective study (Hirayama, 1987), but signiﬁcant trends were
noted in a study in Canada (Kasim et al., 2005) for both indices of
ETS exposure. For smoking by the cohabitant, however, the dose-
response relationship was far from smooth, with RRs of 1.00,dies of brain cancer.
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years exposure.
These results add little to the evidence on ETS as a potential
cause of cancer. Even for endocrine cancer and leukaemia, more
studies are clearly needed before any assessment can be made.3.14. Total cancer incidence
Appendix Table 12 gives results for 15 studies relating ETS
exposure to total, smoking-related and/nonsmoking-related cancer
risk. Some analyses include lung cancers but they are generally not
more than a small fraction of the cancers analysed. Many of the
studies were published before 1990 and appear in our earlier re-
view (Lee, 2002) and only four studies (Chuang et al., 2011; He et al.,
2012; Hill et al., 2007; Iribarren et al., 2001) adjusted for more than
a very small number of potential confounding variables.
Two studies (Miller, 1990; Reynolds et al., 1987) reported RRs, of
6.4 for total cancer and 7.0 for smoking-related cancer, that are
totally implausible bearing in mind the results for individual sites
summarized in the earlier tables (Note that Reynolds et al., 1987
also reported a signiﬁcant association and trend for ETS and total
cancer.). Two further early studies (Hirayama, 1984a and Sandler
et al., 1985a; Sandler et al., 1985b; Sandler et al., 1985c), criticised
for weaknesses of design and analysis (Lee, 1992), reported a
weaker, but signiﬁcant association between ETS exposure and total
cancer. McGhee et al., 2005 reported a signiﬁcant association and
signiﬁcant positive trend, but used an unusual design that asked
the person reporting a cancer death to quantify ETS exposure 10
years earlier for both the case and a living person “who was well
known to the informant”. Hill et al., 2007 reported a signiﬁcant
increase in cancers other than the lung for females in a 1996e99
cohort but not in a 1981e84 cohort, and not formales. Chuang et al.,
2011 showed a clear trend of increasing risk of nonsmoking related
cancer with ETS exposure, although this is reported as not statis-
tically signiﬁcant, but no relationship was seen with total or
smoking-related cancer incidence. He et al., 2012 reported a
signiﬁcantly positive dose-response relationship between risk of
total cancer and ETS exposure for each sex and a signiﬁcant increase
in overall risk from home exposure for the sexes combined. Batty
et al. (2014) found a raised risk in men and a reduced risk in
women, using an analysis based on salivary cotinine level, but
neither estimate was statistically signiﬁcant. Results were similar
when the analysis was based on self-reported ETS exposure. The
remaining six studies (Butler,1988; Gillis et al., 1984; Iribarren et al.,
2001; Miller,1984; Nishino et al., 2001; Sandler et al., 1989) showed
no signiﬁcant association. One (Iribarren et al., 2001) used data
from a large study, and adjusted for many confounders.
A meta-analysis of studies reporting ETS and total cancer
(Fig. 14) gave estimates of 1.10 (1.01e1.20) when the extreme RR
estimate (Miller, 1990) was excluded, and 1.13 (1.03e1.25) when
included. These are the only two meta-analyses of all those con-
ducted that showed signiﬁcant (p ¼ 0.01 and p ¼ 0.03 respectively)
evidence of publication bias. Both prospective and non-prospective
studies (including Miller, 1990) gave analysis results that were
raised but non-signiﬁcantly so.
A meta-analysis of smoking-related cancer (including lung
cancer, Fig. 15) gave a random effects estimate of 1.23 (0.97e1.55).
The largest study presenting results (Chuang et al., 2011),
based on almost 8000 cases, showed no association with total
cancer risk (RR 0.97, 95% CI 0.92e1.02) or with smoking-related
cancer risk (RR 1.00, 95% CI 0.84e1.20) after adjustment for 11
potential confounders. Results from other well designed, large
prospective studies adjusting for relevant confounding variableswould be needed before any conclusion could be reached
regarding the relationship between ETS exposure and total can-
cer risk. It is notable that neither of the two very large American
Cancer Society Cancer Prevention Studies which reported results
for lung cancer (Cardenas et al., 1997; Garﬁnkel, 1981) reported
relevant ﬁndings for total cancer, though having the potential to
do this.3.15. Further meta-analyses
For those cancers for which meta-analyses have been presented
for the main exposure index, Table 1 summarizes results from these
analyses and also, where data permitted, results based on more
speciﬁc exposure indices, estimates for at home and for total
exposure being more commonly available than for workplace or for
childhood exposure. Signiﬁcant increases weremainly only evident
where a signiﬁcantly increased risk had already been found for the
main exposure index. Thus for cervix cancers, estimates of 1.44
(95%CI 1.21e1.72) for at home exposure and 1.53 (1.21e1.94) for
total exposure were similar to that of 1.48 (1.24e1.76) for the main
index, while for total cancer an estimate of 1.12 (1.02e1.23) for at
home exposure was similar to that of 1.10 (1.01e1.20) for the main
index. Exceptionally, an estimate of 1.43 (1.05e1.93) for total
exposure for smoking-related cancer was signiﬁcant whereas that
of 1.23 (0.97e1.55) based on the main-index was not. An estimate
of 1.24 (0.996e1.55) for bladder cancer for total exposure was not
quite signiﬁcant at p < 0.05.4. Discussion
For many of the cancers considered, the meta-analyses con-
ducted show no signiﬁcant positive or negative relationship. These
include nasopharynx cancer, head and neck cancer, various cancers
of the digestive system (stomach, rectum, colorectal, liver,
pancreas) as well as cancers of the endometrium, ovary, bladder
and brain. There are also a number of other cancers less frequently
studied (including oesophagus, colon, gall bladder, all digestive
cancer, lymphoma and the cancers considered in Appendix
Table 11) where the results do not demonstrate a relationship
with ETS exposure. That said, the evidence is quite limited for many
of these cancers, and only for bladder cancer (15 studies) and
pancreatic cancer (11 studies) did more than 10 studies provide
data. It is clearly possible that with additional results, a signiﬁcant
association with some of these cancers might be seen, though even
then interpretation in terms of a causal relationship would be
difﬁcult.
One problem is that for a number of these cancers, an occasional
study reports a very large, and signiﬁcant RR, that is both implau-
sible, given the known effects of smoking and the relative exposure
to smoke constituents from ETS compared to active smoking, and
inconsistent with other published evidence on the relationship
between ETS and the cancer in question. Examples of such aberrant
results are as follows:
 RRs of 7.34e12.0 for head and neck cancer for various indices of
ETS exposure for Tan et al., 1997, with the lower 95% conﬁdence
limit exceeding 2.0, when the vast majority of other RRs shown
in Fig. 2 and Appendix Table 2 are close to 1 and non-signiﬁcant.
 An RR of 5.81 (95% CI 1.84e18.36) for rectal cancer for ETS
exposure from the cohabitant in males for Hooker et al., 2008,
when other results shown in Fig. 4 and Appendix Table 3 from
this study, or for rectal or colorectal cancer from other studies,
give no indication of any effect.
Fig. 14. Results from studies of total cancer incidence.
Fig. 15. Results from studies of smoking-related cancer.
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exposure from the cohabitant for Lo et al., 2007, when the otherresults shown in Fig. 7 and Appendix Table 3 generally suggest
little or no relationship with ETS exposure.
Table 1
Summary of results (RR, 95% CI, number of studies)a from main meta-analyses and additional meta-analyses based on a more consistent exposure deﬁnition.











































































a Results are only shown if at least 4 individual estimates.
b Preferring results for adult exposure from a spouse or cohabitant, the actual estimates included being shown in the Appendix Tables.
c Preferring results for at home exposure or any cohabitant exposure to those for spousal exposure.
d Preferring results for exposure from the mother to that from the father where results for overall childhood exposure are not available.
e Exposure index should be as wide as possible, and must include exposure inside and outside the home.
f Excluding estimates from Tan et al., 1997.
g Excluding estimates from Lo et al., 2007.
h Excluding estimates from Sobti et al., 2006.
i Excluding estimates from Miller, 1990.
P.N. Lee et al. / Regulatory Toxicology and Pharmacology 80 (2016) 134e163 147 An RR of 10.8 (95% CI 1.46e79.1) for all digestive cancers for ETS
exposure from the cohabitant or long-term exposure outside the
home in females for Miller, 1990, which is implausibly high
given the other evidence for ETS and digestive cancers shown in
Figs. 3e7 and Appendix Table 3.
 An RR of 7.16 (95% CI 1.87e27.4) for bladder cancer for an un-
speciﬁed index of ETS exposure in males from Chen et al., 2005,
much higher than seen in the other studies in Fig. 12 and
Appendix Table 8.
These results, all from studies with at most quite limited control
for confounding, and in somecases also evidentweaknesses in study
design, underline the difﬁculties in reaching reliable conclusions
concerning possible effects of ETS exposure on speciﬁc cancer types.
Evidence more suggestive of a relationship is seen for four
cancer endpoints. For cervix, kidney and total cancer meta-analysis
showed a signiﬁcant positive relationship with ETS exposure, while
consistent evidence of an association based on a limited number of
studies was seen for nasosinus cancer. We comment brieﬂy on each
of these relationships.4.1. Nasosinus cancer (Appendix Table 2)
Here there has, somewhat surprisingly, been no additional ev-
idence since our earlier review (Lee, 2002) and our opinion that the
ﬁndings are suggestive, but not conclusive, for a causal relationship,
remains unchanged.4.2. Cervix cancer (Fig. 8 and Appendix Table 4)
An overall RR for ETS exposure of 1.58 (95% CI 1.29e1.93) based
on 17 independent estimates reduces sharply to 1.29 (95% CI
1.01e1.65) after attention is restricted to ﬁve estimates adjusted for
HPV infection or sexual activity. In viewof the possibility of residual
confounding, the adjusted estimate cannot be regarded as
providing convincing evidence of a true relationship. However, the
available data are suggestive of one, requiring additional evidence
for clariﬁcation.
4.3. Kidney cancer (Fig. 11 and Appendix Table 7)
Meta-analysis based on six independent estimates from four
studies shows a signiﬁcant association (RR 1.33, 95% CI 1.04e1.70),
with no evidence of heterogeneity. While this is suggestive of a
possible causal relationship, the limited number of studies and
lack of association seen in the only prospective study emphasise
the need for more evidence before any reliable conclusion can be
reached.
4.4. Total cancer (Fig. 11 and Appendix Table 12)
After excluding a highly implausible RR of 6.40 (95% CI
2.34e17.5) from Miller, 1990, the combined RR based on 18 esti-
mates for total cancer (including lung cancer) is signiﬁcant at 1.10
(95% CI 1.01e1.20). However, bearing in mind the lack of
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founding variables (Chuang et al., 2011; Iribarren et al., 2001), the
limited control for confounding in many of the other studies and
the lack of signiﬁcant association of ETS exposure with smoking-
related cancer or cancer other than lung cancer, the evidence
here must be regarded as inconclusive. In any case, the interpre-
tation of results for overall cancer risk is not straightforward, given
that the contribution of different cancers varies between
populations.
In interpreting the ﬁndings, it should be noted that for kidney
cancer and total cancer, and also for cervix cancer when consid-
ering studies that adjust for HPV infection and/or sexual activity,
the meta-analysis RRs are only marginally signiﬁcant, with the
lower 95% conﬁdence limit of the RR only just above 1.0. In view of
the number of potential biasing factors noted in the introduction,
and the likelihood that some of these are relevant, one can hardly
conclude that a causal relationship has deﬁnitely been demon-
strated for any of these relationships.
Our main meta-analyses used an exposure index which was
chosen from each study to be as close as possible to spousal
exposure. However, for a number of studies the exposure index
used varied markedly from this. While these meta-analyses include
data from as many studies as possible, it may seem better to restrict
attention to more consistent exposure deﬁnitions. In practice
conclusions to be drawn from these analyses differed little from
those based speciﬁcally on exposure at home, at work, or in
childhood or on total exposure.
Problems common to many studies include small sample size,
inadequate control of potential confounding, failure to ensure that
nonsmokers actually were so with only the studies of Slattery et al.,
1989 and Batty et al., 2014 determining cotinine levels to identify
misclassiﬁed smokers. Reliance on death certiﬁcates for diagnosis
of cancer and use of proxy respondents in some studies is also a
problem.
Despite the fact that formal tests of publication bias were, with
the exception of the meta-analyses for total cancer incidence, non-
signiﬁcant, the possibility of such a bias is clearly a live one, as is
evident from the fact that so few of the prospective studies have
presented results for a wide range of cancer types. Thus, of the
studies considered in Table 1, only the nationwide study in Japan
(Hirayama, 1984b, 1985; 1987) which presented limited results for
17 sites, the study inMiyagi, Japan (Nishino et al., 2001), which gave
results for 9 sites, and the European Study (Chuang et al., 2011),
which gave results for 13 studies, qualify in this respect. There are
also other large prospective studies including the American Cancer
Society Prevention Study I (Garﬁnkel, 1981) and II (Cardenas et al.,
1997) which give results for lung cancer, but not for the cancers
considered here. It certainly seems likely that, for some prospective
studies, analyses relating ETS exposure to cancer of some of the
sites we consider were conducted, but never published as no sig-
niﬁcant association was found.
Recall bias is also a potential problem given that so much of the
data derives from case-control studies. There is a growing tendency
to ask ever more detailed questions on ETS exposure and to esti-
mate risks using a comparison group of subjects who reported no
exposure from any source. While there are attractions in using a
totally unexposed group, these may be superﬁcial. In practice it is
unlikely that anyone goes through life without encountering ETS so
that those classiﬁed as totally unexposed may include only those
who have no exposure of concern to them. Concern may be higher
for those with cancer who seek a reason for their disease.
Consistency and plausibility of ﬁndings is another important
issue. It is difﬁcult to be convinced by evidence from small studies
reporting signiﬁcant associations, when better designed and larger
studies do not do so. Nor is it easy to accept claims that ETSmarkedly increases risk of a cancer shown not to be associated with
active smoking. Given that active smokers would, on average, have
higher ETS exposure than exposed nonsmokers, such results, if not
due to bias, could only be explained by a model in which main-
stream smoke protected against cancer risk and ETS increased it.
This seems unlikely.
In their latest evaluation of the evidence relating ETS exposure
to cancer (International Agency for Research on Cancer, 2012),
stated that for most of the cancers considered here, including
kidney and cervix, the data are “conﬂicting and sparse”. Apart from
lung cancer and breast cancer, not considered here, they only
commented speciﬁcally in their “Synthesis” section on upper aer-
odigestive cancer, which they regarded as “less than causal”, cancer
of the nasopharynx, where the evidence was regarded as “contra-
dictory”, and sinonasal cancer, where there was “some evidence”
that ETS exposure “increases the risk”. While for some endpoints,
they considered studies that were not restricted to never smoking
subjects (Coker et al., 2002; McGlynn et al., 2006; Slattery et al.,
2003; Tay and Tay, 2004), and while for a study of the maxillary
sinus (Fukuda and Shibata, 1990) the RR that IARC quoted was in
fact the chi-square statistic, the real RR not being statistically sig-
niﬁcant, their conclusions were broadly in line with ours, although
we consider the evidence for cancer of the cervix to be suggestive of
a causal relationship.
In the conclusions section of their review the US Surgeon
General, 2006 stated that the evidence for nasal sinus cancer
was suggestive of a causal relationship, while that for nasopharynx
cancer and cervix cancer was inadequate. These conclusions are
similar to those of IARC. At about the same time, the California EPA
published their report (California Environmental Protection
Agency, 2005) which, for the cancers we consider, concluded
that there was “strong evidence that ETS exposure increases the
risk of nasal sinus cancers in nonsmoking adults”, that “studies
suggest an association between ETS exposure and elevated risk of
nasopharyngeal cancers” and that the evidence suggests “that
exposure to ETS may increase the risk of cervical cancer”. For other
cancer sites the evidence was regarded as “limited” and
“inconclusive”.
The possibility that, in never smokers, ETS exposure increases
risk of cancer of one or more of the sites considered cannot be
dismissed and further studies and further analyses of existing data
are certainly needed. However, at this point in time, the epide-
miological evidence, taken as a whole, does not convincingly
demonstrate the existence of any cause and effect relationship.
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Appendix
This Appendix is made up of tables giving details of each of the
studies considered, the relevant results they provide (or which can
be estimated from the results they provide) and the results of the
meta-analyses carried out. Each of the meta-analyses is presented
in a forest plot within the text.
Appendix Table 1
Studies providing data on ETS and cancer other than the lung or breast in never smokers.
Studya Location Designb Cancer site(s) Potential confounding variables adjusted for
Gillis et al., 1984 Scotland P Total (not lung) Age
Hirayama, 1984a; 1985;
1987
Japan, six prefectures P Total and 17 sitesc Age of husband, occupation of husbandd
Miller, 1984 USA, Pennsylvania CC Total Age
Sandler et al., 1985a;
Sandler et al., 1985b;
Sandler et al., 1985c
USA, N Carolina CC Total and nine categoriese None
Kabat et al., 1986 USA, 18 hospitals CC Bladder None
Reynolds et al., 1987 USA, California P Total, smoking-related Age, income
Butler, 1988 f USA, California P Total, smoking-related,
cervix
Age
Sandler et al., 1989; Sandler
et al., 1988
USA, Maryland P Total, smoking-related, not
smoking-related, colon
Age, housing quality, schooling, marital status
Burch et al., 1989 Canada, Alberta and
Ontario
CC Bladder Age, area of residence
Slattery et al., 1989 USA, Utah CC Cervix Age, education, church attendance, number of sexual partners
Fukuda and Shibata, 1990 Japan, Hokkaido CC Nasal cavity None
Miller, 1990 USA, Pennsylvania CC Total Age
Yu et al., 1990 China, Guangzhou CC Nasopharynx Age, sex
Coker et al., 1992 USA, N Carolina CC Cervical intraepithelial
neoplasm grades II and
greater (CIN II)
Age, education, race, number of Pap smears, number of partners, genital
warts
Mizuno et al., 1992 Japan CC Pancreas None
Ryan et al., 1992 Australia, Adelaide CC Brain Age
Kreiger et al., 1993 Canada, Ontario CC Kidney Age, body mass index
Zheng et al., 1993 USA, national CC Nasal cavity Age, alcohol use
Hirose et al., 1996 Japan, Nagoya CC Cervix, endometrium Age, year of ﬁrst visit
Hurley et al., 1996 Australia, Melbourne CC Brain Age, sex, reference date
Vaughan et al., 1996 USA, ﬁve cancer registries CC Nasopharynx Age, sex
Blowers et al., 1997 USA, California CC Brain None
Tan et al., 1997 USA, Ohio CC Head/neck None
Cheng et al., 1999 Taiwan CC Nasopharynx Age, sex, race, educational level, family history of nasopharynx cancer
Jee et al., 1999 Korea P Stomach, liver, cervix Age, socioeconomic status, residency, husband’s age, vegetable
consumption, occupation
Johnson et al., 1999 Canada CC Brain None stated (in abstract)
Scholes et al., 1999 USA, Washington State CS Cervixg Age, number of sexual partners, age at ﬁrst intercourse
Armstrong et al., 2000 Malaysia CC Nasopharynx Diet
Yuan et al., 2000 China, Shanghai CC Nasopharynx Age and seven othersh
Zhang et al., 2000 USAi CC Head/neck None
Iribarren et al., 2001 USA, California CS All cancers Age and 10 othersj
Nishino et al., 2001 Japan, Miyagi P Total, smoking-related and
nine sitesk
Age and othersl
Mao et al., 2002 Canada CC Stomach Age and seven othersm
Zeegers et al., 2002 Netherlands P Bladder Age and sex
Goodman and Tung, 2003 USA CC Ovary Age, ethnicity, education, study site, use of oral contraceptive pill, parity,
tubal ligation
Wu et al., 2003 Taiwan CC CIN II Age, education level, number of pregnancies, age at ﬁrst intercourse,
cooking in the kitchen during ages 20e40
You et al., 2003 China CC Oesophagus, stomach, liver Unspeciﬁed but states that “ETS and confounders information was
collected …”
Villeneuve et al., 2004 Canada CC Pancreas Age, sex, body mass index, income adequacy, province of residence
Chen et al., 2005 Taiwan CC Bladder Age, BMI, cumulative arsenic, hair dye usage, education
Hu et al., 2005 Canada CC Renal cell Age, province, education, body mass index, alcohol use, total
consumption of meat and of vegetables and fruit
Kasim et al., 2005 Canada CC Leukaemia Age, sex, BMI, benzene, ionising radiation
McGhee et al., 2005 Hong Kong CC All cancers Age and education (and sex for sexes-combined analysis)
Phillips et al., 2005 USA, western Washington
State
CC Intracranial meningioma Age, sex, education
Trimble et al., 2005 USA, Washington County P Cervix Age, education, marital status, religious attendance (1963 cohort only)
Baker et al., 2006 USA, New York state CC Ovary Age, residence, income, usual BMI, history of vaginal infection, year of
participation, duration of breastfeeding
Bjerregaard et al., 2006 Three European countries P Bladder Age, fruit and vegetables, ETS exposure at the other timepoint
(childhood, adulthood)
Gallicchio et al., 2006 USA, Washington County P Pancreas Age, education, marital status
Lilla et al., 2006 Germany CC Colorectum Age, sex, NSAID use, endoscopy, family history, alcohol, red meat,
education, BMI
Samanic et al., 2006 Spain CC Bladder Age, region, fruit/vegetable consumption, high-risk occupation
Sobti et al., 2006 n India, Chandigarh and
Punjab
CC Cervix None
Alberg et al., 2007 USA, Washington County P Bladder Age, education, marital status
Al-Zoughool et al., 2007 Six European countries P Endometrium
(continued on next page)
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Appendix Table 1 (continued )
Studya Location Designb Cancer site(s) Potential confounding variables adjusted for
Unspeciﬁed, but other analyses were adjusted for age, centre, BMI,
physical activity, OC use, parity, education, alcohol, HRT use, age at
menopause
Hassan et al., 2007 USA, Texas CC Pancreas Age, sex, race/ethnicity, diabetes, alcohol, education, state of residence,
marital status
Hill et al., 2007 New Zealand P Total (not lung) Age, ethnicity, marital status, education, labour force status, household
equivalized income, household car access, tenure, deprivation index
Jiang et al., 2007 USA, Los Angeles County CC Bladder Age, race/ethnicity, education, ETS exposure in other settings
Lo et al., 2007 Egypt CC Pancreas Age, sex, residence
Paskett et al., 2007 USA, nationwide P Colorectum, colon, rectum Age, ethnicity, study, family history, physical activity, NSAID use,
alcohol, hormone therapy use, colonoscopy, diabetes, dietary calcium,
ﬁbre and fat, haemoglobin, waist circumference, red meat intake
Tsai et al., 2007 Taiwan CC CIN II Age, education, prior Pap smears, sexual partners, age at ﬁrst
intercourse, family history, cooking oil fume exposure, HPV infection
Gram et al., 2008 Norway and Sweden P Ovary Age, nulliparous, menopausal status, duration of hormonal
contraceptive use
Hassan et al., 2008 USA, Texas CC Liver Age, sex, race, education, marital status, residence, hepatitis C virus,
hepatitis B virus, diabetes, alcohol consumption, family history of cancer
Hooker et al., 2008 USA, Washington County P Rectum Age, education, marital status
Kordi Tamandani et al.,
2008; Shekari et al., 2012
n
India, Chandigarh CC Cervix None (earlier analysis); Age, oral contraceptives (later analysis)
Lee et al., 2008 Europe, Latin America
and USA
CC Head/neck Age, sex, race, study centre, education, alcohol consumption
Ramroth et al., 2008 Germany CC Larynx Age, sex, alcohol consumption, education
Theis et al., 2008 USA, Florida/Georgia CC Kidney Age, sex, race, BMI, alcohol consumption
Bao et al., 2009 USA, nationwide P Pancreas Age, height, diabetes, BMI
Baris et al., 2009 USA, three states CC Bladder Age, race, sex, Hispanic status, state of residence
Duan et al., 2009 USA, Los Angeles County CC Oesophagus, stomach Age, sex, BMI, ethnicity
Lee et al., 2009 10 European countries CC Head/neck, oesophagus Age, sex, education, study centre, alcohol consumption, duration of
exposure
Verla-Tebit et al., 2009 Germany CC Colorectal Age, sex, education, family history of colorectal cancer, BMI, fruit/
vegetable intake, red meat intake, NSAID use, alcohol consumption,
physical activity, colonoscopy, HRT useo
Heinen et al., 2010 Netherlands P Pancreas Age, BMI, education
Peppone et al., 2010 USA, New York State/
Buffalo
CC Colorectal Age, sex, BMI, place of residence, race, education, income, family history
of colorectal cancer, vegetable intake, meat intake, alcohol
consumption, aspirin use
Tao et al., 2010 China, Shanghai CC Bladder Age, education, tea consumption, vegetable intake
Yang et al., 2010 Poland, Warsaw/Lodz CC Endometrium Age, study site, education, menarche, parity, oral contraceptive use, HRT
use, BMI, menopausal status
Chuang et al., 2011 10 European countries P Total, smoking and
nonsmoking related and 13
sitesp
Age, sex and othersq
Louie et al., 2011 Europe, Asia and South
America
CC Cervix Age, study country, education of husband and wife, lifetime sexual
partners of husband, history of sexually transmitted infections, age at
ﬁrst intercourse of wife, oral contraceptives, parity and Pap smear
history in previous year
Lu et al., 2011 USA, California P Lymphoma Age, race, alcohol consumption 1 year before study entry
He et al., 2012 China, Xi’an P Total Age, sex, marital status, occupation, education, alcohol use, diastolic
blood pressure, triglyceride and total cholesterol levels, BMI
Zheng et al., 2012 Egypt, 3 areas CC Bladder Age, area of residence, urban/rural residence, education, history of
schistosomiasis, history of urinary tract infection, menopausal status in
women
Ferreccio et al., 2013 Chile, 2 regions CC Bladder Age, sex, socioeconomic status, arsenic exposure
Lin et al., 2013 Japan, 45 areas P Pancreas Age, BMI, history of diabetes
Stingone et al., 2013 USA, North Carolina CC Head/neck Age, sex, race, education, consumption of fruit/vegetables and alcohol
Troy et al., 2013 USA, Pennsylvania CC Head/neck Age, sex, race, recruitment period, alcohol drinking status, history of
cancer, education
Wu et al., 2013 Taiwan CC Urothelial Age, sex, education, alcohol consumption, urinary arsenic
Abbas et al., 2014 India, Lucknow CC Cervix CYP1A1m1 genotype
Batty et al., 2014 UK, nationwide P Total Age, socioeconomic status, alcohol intake, physical activity, history of
heart disease, cancer and diabetes
Diver et al., 2014 USA, nationwide P Lymphoma Age, sex, race, education, family history of haematopoietic cancer,
height, BMI, physical activity, alcohol use, use of NSAIDS, hormone
replacement therapy use
a Studies are given in order of ﬁrst publication.
b Study design P ¼ prospective CC ¼ case-control CS ¼ cross-sectional.
c Mouth/pharynx, oesophagus, stomach, colon, rectum, liver, gall bladder, pancreas, nasal cavity, bone, skin, cervix, ovary, bladder, brain, malignant lymphoma, leukaemia.
d Occupation of husband only adjusted for in analyses of total and stomach cancer.
e Smoking related, not smoking related, digestive, bone, brain, cervix, female genital, endocrine and haematopoietic.
f Results for spouse-pairs cohort only considered as the other (AHSMOG) cohort included ex-smokers.
g Includes only low-grade cervical abnormalities: cervical intraepithelial neoplasia grade III and invasive cancer cases were excluded.
h Education, preserved food intake, oranges/tangerines intake, exposure to smoke from heated rapeseed oil and from burning coal during cooking, occupational exposure to
chemical fumes, history of chronic ear and nose conditions, family history of nasopharynx cancer.
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i Memorial Sloan-Kettering Cancer Centre.
j Race/ethnicity, education level, marital status, alcohol consumption, physical activity at work, serum total cholesterol, body mass index, hypertension, diabetes, individual
occupational hazards.
k Stomach, colon, rectum, liver, gall bladder, pancreas, cervix uteri, corpus uteri, ovary.
l Age only for liver, gall bladder, pancreas, cervix uteri, corpus uteri and ovary. For other sites analyses adjusted for age, study area, alcohol, green and yellow vegetables,
fruit. For stomach analyses also adjusted for miso-soup, and pickled vegetables. For colon and rectum analyses also adjusted for meat.
m Province, education, social class, meat consumption, vegetable consumption, fruit, juices.
n There may be some overlap of subjects between the studies reported by Sobti et al., 2006 and by Kordi Tamandani et al., 2008 and Shekari et al., 2012.
o HRT use was only adjusted for in analyses restricted to female participants.
p Upper aero-digestive tract, stomach and cardia, colorectal, pancreas, cervix uteri, endometrium, ovary, prostate, bladder, kidney, brain and nervous system, thyroid,
lymphoma.
q Age and sex only for upper aero-digestive tract, ovary, bladder and kidney. For other sites, analyses adjusted for age, sex, study centre, education, alcohol consumption,
BMI, physical activity, vegetable intake, fruit intake, non-alcoholic energy intake, adulthood passive smoking. For stomach/cardia, and colorectal analyses also adjusted for red
meat intake and processed meat intake. For pancreas analysis also adjusted for self-reported diabetic status. For cervix and endometrium, analyses also adjusted for age at
menarche, ever use of oral contraceptives, parity and menopausal status.
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ETS exposure and cancer of the head and neck in never smokers.a
Studyb Country Source (timing) of ETS expos
Cancer of the nasopharynx
Yu et al., 1990 China Spouse (ever)g
Cohabitant (ever)
Mother (childhood age 10)g
Father (childhood age 10)g
Cohabitant (childhood age 1
Vaughan et al., 1996 USA Cohabitant (adulthood)
Cohabitant (childhood)
Cheng et al., 1999 Taiwan Cohabitant (adulthood)
Cohabitant (childhood)
Armstrong et al., 2000 Malaysia Cohabitant (adulthood)
Parent (childhood)






Random effects meta-analysis based on 5 estimates
Cancer of the nasal sinus
Hirayama, 1984a * Japan Spouse (ever)
Fukuda and Shibata, 1990 Japan Cohabitant (unspeciﬁed)n
Zheng et al., 1993 USA Spouse (ever)
Head and neck cancer
Hirayama, 1987 * Japan Spouse (ever)
Tan et al., 1997 USA Spouse (ever)
Co-worker (ever)
Spouse or co-worker (ever)
Zhang et al., 2000 USA Spouse or partner (current)
Cohabitant (ever)
Co-worker (ever)





Ramroth et al., 2008 Germany Partner or co-worker (ever)
Lee et al., 2009 10 European countries Home/work (ever)
Home (ever)
Work (ever)
Chuang et al., 2011 * 10 European countries Childhood (ever)
Stingone et al., 2013 USA Home (ever)
Troy et al., 2013 USA Childhood (ever)ure Sex Number
of casesc
RR (95% CI)d Dose
responsee
Adjustedf
MþF 72 0.8 (0.4e1.9)h e ac (1)
MþF 142 0.7 (0.4e1.4) e ac (1)
MþF 63 0.7 (0.3e1.5) e ac (1)
MþF 109 0.6 (0.3e1.2) e ac (1)
0)g MþF 59 0.7 (0.4e1.3) e ac (1)
MþF 19i No increase No ac (1)
MþF 19i No increase No ac (1)
MþF 178 0.7 (0.5e1.2)h No ac (4)
MþF 178 0.6 (0.4e1.0) d1 ac (4)
MþF (282)j No association e ac (1)
MþF (282)j 2.28 (1.21e4.28)h e ac (1)
F 156 3.09 (1.48e6.46)h d2 ac (9)
M 17 1.53 (0.26e8.93)h No ac (9)
F 139 2.84 (1.34e6.00) d3 ac (9)
M 168 1.32 (0.63e2.76) No ac (9)
F 187 2.88 (1.39e5.96) d4 ac (9)
M 63 0.92 (0.41e2.03) No ac (9)
F 44 3.36 (1.41e8.05) d5 ac (9)
M 37 1.42 (0.56e3.58) No ac (9)
F 151 2.95 (1.41e6.19) d6 ac (9)
M 82 1.17 (0.54e2.55) No ac (9)
F 161 2.96 (1.42e6.20) d7 ac (9)
M 97 1.26 (0.59e2.71) No ac (9)
1.40 (0.71e2.76)l
F 28 1.63 (0.61e4.35)m d8 c (1)
F 35 1.96 (0.84e4.57)m d9 u
M 9 No association No r
M 28 3.0 (1.0e8.9) e ac (1)
M <28o 4.8 (0.9e24.7) No ac (1)
F 22 Not available No c (1)
F 21 7.34 (2.44e22.1)m,h e u
M 22 1.14 (0.41e3.23)m,h e u
F 18 8.96 (2.43e33.0)m e u
M 20 12.0 (3.77e38.0)m e u
F 21 8.00 (2.55e25.1)m e u
M 23 3.78 (1.37e10.4)m e u
MþF 13 0.9 (0.2e5.2)h e u
MþF 26 2.03 (0.77e5.40)m No u
MþF 26 1.86 (0.68e5.11)m No u
MþF 489 1.07 (0.85e1.34)p e ac (5)
MþF 484 1.11 (0.89e1.39)m,h,p d10 ac (5)
MþF 484 0.95 (0.76e1.19)m,p No ac (5)
MþF 9q 2.00 (0.39e10.70)h e ac (3)
MþF 111r 1.87 (1.08e3.23) d11 ac (5)
MþF 34q 1.98 (0.77e5.07) No ac (5)
MþF 111r 1.12 (0.72e1.75)m,h No ac (5)
MþF 34q 1.61 (0.76e3.43)m,h No ac (5)
MþF 111r 1.43 (0.92e2.22)m d12 ac (5)
MþF 34q 1.35 (0.64e2.87)m No ac (5)
MþF 52 1.16 (0.63e2.11)m,h e ac (1)
MþF 125 0.82 (0.53e1.27)h No ac (5)
MþF 184 1.19 (0.80e1.76)h d13 ac (6)
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Studyb Country Source (timing) of ETS exposure Sex Number
of casesc
RR (95% CI)d Dose
responsee
Adjustedf
Childhood (mother) MþF 119 1.17 (0.72e1.90) e ac (6)
Childhood (father) MþF 119 1.06 (0.58e1.96) e ac (6)
Childhood (siblings) MþF 119 3.46 (1.28e9.39) e ac (6)
Childhood (other household
members)
MþF 119 0.77 (0.24e2.50) e ac (6)
Random-effects meta-analysis based on 10 estimates (including Tan et al.) 1.20 (0.95e1.52)s
Random-effects meta-analysis based on 8 estimates (excluding Tan et al.) 1.11 (0.95e1.29)t
a Results are not included for 10 studies (Airoldi et al., 2005; Chen et al., 1988; Escribano Uzcudun et al., 2002; Guo et al., 1995; Kashigar et al., 2013; Nesic et al., 2010;
Schantz et al., 1997; Vineis et al., 2005; Yu et al., 1986, 1988) as the analyses were not restricted to never smokers.
b Prospective studies are marked *. All other studies are case control.
c Number of cases: number among never smokers except where stated.
d RR (95% CI): estimated from data provided where necessary.
e Dose response: “-” indicates dose response not reported, “No” indicates dose response studied but no signiﬁcant trend seen, “d1”, “d2” …“d13” indicate dose response
studied, signiﬁcant trend with more detailed data as follows: d1 A signiﬁcant negative dose-related trend was noted in relation to duration of exposure and cumulative
exposure but not in relation to number of smokers in the household (childhood data). d2 RRs 1.0, 3.02, 3.18 for 0, <20, 20þ years lived with smoking spouse (trend p¼ 0.003).
Relative risks 1.0, 3.16, 3.02 for 0, <20, 20þ cigs/day by spouse (trend p¼ 0.004). RRs 1.0, 3.15, 2.45, 6.76 for 0, <20, 20e39, 40þ pack-years by spouse (trend p < 0.001). d3 RRs
1.0, 2.47, 3.28 for 0, <3, 3þ hours ETS at work (trend p¼ 0.01). d4 RRs 1.0, 2.65, 2.62, 4.35 for 0, <20, 20e39, 40þ cigs/day by household member (trend p¼ 0.003). d5 RRs 1.0,
2.36, 5.90 for 0, <20, 20þ cigs/day bymother (trend p¼ 0.003). d6 RRs 1.0, 2.46, 3.48 for 0, <20, 20þ cigs/day by father (trend p¼ 0.004). d7 RRs 1.0, 2.33, 3.83, 2.13 for 0, <20,
20e39, 40 þ cigs/day by household member (trend p ¼ 0.01). d8 RRs were 1.00, 1.67, 2.02, 2.55 for 0, 1e14, 15e19, 20 þ cigs/day smoked by the husband (one-tailed trend
p ¼ 0.025). d9 RRs were 1.00, 1.40, 5.73 for 0, 1, 2 þ smokers in the household (trend p < 0.05). d10 RRs were 1.00, 1.28, 1.60 for no exposure, 1e15 or >15 years exposure
(trend p¼<0.01). Includes Central Europe, Tampa, Latin America, Los Angeles and Puerto Rico studies only. d11 RRs were 1.00, 1.38, 2.15 for no exposure, 1e15 or >15 years
exposure (trend p ¼ 0.007). d12 RRs were 1.00, 1.04, 1.92 for no exposure, 1e15 or >15 years exposure (trend p ¼ 0.025). d13 RRs were 1.00, 1.06, 6.76 for exposure to 1, 2
3 þ household smokers (trend p ¼ 0.04). Cigarettes per day and pack-years showed no dose-response relationship.
f Adjustment factors indicated by codes u, unadjusted; a, adjusted for age; c(n), adjusted for n confounding variables other than age (see Appendix Table 1); r, number of
smokers in the household not included as a signiﬁcant factor in multiple regression analysis after adjustment for sinusitis and/or polyps and woodworking.
g Reference group is never exposed at home from any source.
h RR included in meta-analysis.
i Results are for differentiated squamous cell carcinoma.
j Number of cases in never smokers not known e number given (in brackets) is total for study and includes cancers in smokers.
k Reference group is never exposed at home or work from any source.
l Heterogeneity chisquared is 17.23 on 4 degrees of freedom (p ¼ 0.0017); Egger test p ¼ 0.49.
m Results estimated from data reported.
n The source paper does not make clear the time period the ETS exposure relates to.
o Results are for maxillary cancer only.
p Includes Central Europe, Tampa, Latin America, Los Angeles and Houston studies only.
q Results are for cancer of the larynx and hypopharynx.
r Results are for cancer of the oral cavity and oropharynx.
s Heterogeneity chisquared is 14.59 on 9 degrees of freedom (p ¼ 0.10). Egger test p ¼ 0.20.
t Heterogeneity chisquared is 3.47 on 7 degrees of freedom (p ¼ 0.84). Egger test p ¼ 0.53.
Appendix Table 3
ETS exposure and cancer of the digestive system in never smokers.a
Studyb Country Source (timing) of ETS exposure Sex Number
of casesc
RR (95% CI)d Dose
responsee
Adjustedf
Cancer of the oesophagus
Hirayama, 1987 * Japan Spouse (ever) F 58 Not available No c (1)
You et al., 2003 China Unspeciﬁed MþF 84 1.72 (1.0e3.1) d1 c (?)
Duan et al., 2009 USA Childhood (ever) 38 0.55 (0.27e1.12)g No ac (3)
Adulthood (ever) MþF 38 1.64 (0.79e3.42)g,h No ac (3)
Lee et al., 2009 Europe Home/work (ever) MþF 24 0.76 (0.27e2.12) No ac (5)
Home (ever) MþF 24 0.72 (0.27e1.91)g No ac (5)
Work (ever) MþF 24 0.96 (0.35e2.61)g No ac (5)
Stomach cancer
Hirayama, 1984a * Japan Spouse (ever) F 854 1.01 (0.87e1.18)g,i No c (2)
Jee et al., 1999 * Korea Spouse (ever) F 197 0.94 (0.68e1.29)g,i No ac (5)
Nishino et al., 2001 * Japan Spouse (current) F 83 0.98 (0.59e1.60)i e ac (6)
Cohabitant (current) F 83 0.87 (0.54e1.40) e ac (6)
Mao et al., 2002 Canada Cohabitant or Co-worker (ever) M 132 1.08 (0.64e1.82)g,i,j d2 ac (7)
You et al., 2003 China Unspeciﬁed MþF 85 1.33 (0.8e2.3)i d1 c (?)
Duan et al., 2009 USA Childhood (ever) MþF 211 0.81 (0.56e1.17)g,k No ac (3)
Adulthood (ever) MþF 226 1.13 (0.79e1.62)g,i,l d3 ac (3)
Chuang et al., 2011 * 10 European countries Childhood (ever) MþF 109 0.87 (0.57e1.31)i d4 ac (12)
Random effects meta-analysis based on 7 estimates 1.02 (0.91e1.14)m
Colon cancer
Hirayama, 1987 * Japan Spouse (ever) F 142 Not available No c (1)
Sandler et al., 1988 * USA Cohabitant (ever) F 215 0.74 (0.56e0.97) e a
M 49 2.99 (1.77e5.04) e a
Nishino et al., 2001 * Japan Spouse (current) F 48 1.10 (0.54e2.40) e ac (5)
Cohabitant (current) F 48 1.10 (0.58e2.20) e ac (5)
Paskett et al., 2007 * USA Cohabitant or co-worker (ever) F z252 1.00 (0.63e1.59) e ac (15)
Rectal cancer
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Studyb Country Source (timing) of ETS exposure Sex Number
of casesc
RR (95% CI)d Dose
responsee
Adjustedf
Hirayama, 1987 * Japan Spouse (ever) F 112 Not available No c (1)
Nishino et al., 2001 * Japan Spouse (current) F 31 1.90 (0.87e4.20)i e ac (5)
Cohabitant (current) F 31 1.60 (0.75e3.40) e ac (5)
Paskett et al., 2007 * USA Cohabitant or co-worker (ever) F z32 0.63 (0.21e1.84)i e ac (15)
Hooker et al., 2008 * USA
1963 cohort Cohabitant (baseline) F 56 1.03 (0.58e1.81)i e ac (2)
Cohabitant (baseline) M 12 5.81 (1.84e18.36)i e ac (2)
1975 cohort Cohabitant (baseline) F 54 1.04 (0.54e1.98)i e ac (2)
Cohabitant (baseline) M 13 1.10 (0.24e4.97)i e ac (2)
Random effects meta-analysis based on 6 estimates 1.36 (0.81e2.26)n
Colorectal cancer
Lilla et al., 2006 Germany Childhood, partner or workplace (ever) MþF 237 0.79 (0.53e1.20) No ac (8)
Childhood (ever) MþF 237 0.82 (0.57e1.18)g e ac (8)
Partner/workplace (ever) MþF 237 1.21 (0.84e1.75)g,i e ac (8)
Paskett et al., 2007 * USA Cohabitant or co-worker (ever) F 284 0.93 (0.61e1.42)i e ac (15)
Verla-Tebit et al., 2009 Germany Childhood (ever) F 148 1.26 (0.77e2.08)g e ac (10)
M 104 0.43 (0.23e0.79)g e ac (9)
Adulthood (ever) F 148 1.28 (0.77e2.08)g e ac (10)
M 104 1.06 (0.58e1.93)g e ac (9)
Spouse (ever) F 148 1.58 (0.96e2.61)g,i No ac (10)
M 104 0.59 (0.31e1.12)g,i e ac (10)
Total (ever) F 148 1.01 (0.56e1.80) No ac (10)
M 104 0.59 (0.31e1.15) No ac (9)
Peppone et al., 2010 USA Home/work/other locations (current) F 284 0.97 (0.61e1.53)o,i No ac (10)
M 205 1.58 (0.93e2.69)o,i d5 ac (10)
Chuang et al., 2011 * 10 European countries Childhood (ever) MþF 747 0.97 (0.83e1.14)i No ac (12)
Random effects meta-analysis based on 7 estimates 1.06 (0.88e1.29)p
Liver cancer
Hirayama, 1987 * Japan Spouse (ever) F 226 Not available No c (1)
Jee et al., 1999 * Korea Spouse (ever) F 83 0.74 (0.46e1.17)g,i No ac (5)
Nishino et al., 2001 * Japan Spouse (current) F 20 1.20 (0.45e3.20)i e a
You et al., 2003 China Unspeciﬁed MþF 79 1.13 (0.6e1.9)i d1 c (?)
Hassan et al., 2008 USA Childhood (ever) F 47 0.70 (0.36e1.37)g No ac (10)
M 41 0.31 (0.11e0.84)g No ac (10)
Adulthood (ever) F 47 0.89 (0.45e1.75)g,i No ac (10)
M 41 0.43 (0.17e1.08)g,i No ac (10)
Lifetime (ever) F 47 0.71 (0.34e1.49)g No ac (10)
M 41 0.19 (0.08e0.45)g No ac (10)
Random-effects meta-analysis based on 5 estimates 0.84 (0.63e1.12)q
Gallbladder cancer
Hirayama, 1987 * Japan Spouse (ever) F 91 Not available No c (1)
Nishino et al., 2001 * Japan Spouse (current) F 23 0.66 (0.24e1.90) e a
Pancreatic cancer
Hirayama, 1987 * Japan Spouse (ever) F 127 Not available No c (1)
Nishino et al., 2001 * Japan Spouse (current) F 19 1.20 (0.45e3.10)i e a
Gallicchio et al., 2006 * USA
1963 cohort Cohabitant (baseline) MþF 22 1.1 (0.4e2.8)i e ac (2)
1975 cohort Cohabitant (baseline) MþF 34 0.9 (0.4e2.3)i e ac (2)
Bao et al., 2009 * USA Mother (childhood) F 95 1.52 (0.97e2.39)r e ac (3)
Father (childhood) F 133 0.76 (0.54e1.07)r e ac (3)
Workplace/home (current) F 151 0.94 (0.62e1.41)g e ac (3)
Cohabitant (adulthood) F 151 1.05 (0.76e1.46)g,i,s No ac (3)
Heinen et al., 2010 * Netherlands Childhood (ever) F 117 0.90 (0.54e1.50) e ac (2)
Spouse (current) F 62 0.78 (0.44e1.39)i e ac (2)
Workplace (ever) F 87 0.82 (0.51e1.32)g No ac (2)
Workplace/home (current) F 101 1.11 (0.72e1.71)g No ac (2)
Chuang et al., 2011 * 10 European countries Childhood (ever) MþF 121 1.32 (0.85e2.04) d6 ac (11)
Home/work (ever) MþF 105 1.54 (1.00e2.39)i,t,u e ac (5)
Childhood and home/work (ever) MþF 48 3.83 (1.34e10.9)t,u e ac (5)
Lin et al., 2013 * Japan Home (current) F 164 1.20 (0.87e1.67)i No ac (2)
Home (childhood) F 202 1.21 (0.87e1.68) e ac (2)
Outside home (current) F 147 1.13 (0.80e1.58)g Np ac (2)
Any (ever) M 53 No association e e
Random effects meta-analysis based on 7 estimates (prospective studies) 1.13 (0.95e1.36)v
Mizuno et al., 1992 Japan Home (childhood) F 35 0.72 (0.28e1.86)g,i e u
M 5 0.11 (0.01e2.60)g,i,w e u
Villeneuve et al., 2004 Canada Cohabitant or co-worker:
(childhood only) MþF 23 1.37 (0.46e4.07) e ac (4)
(adult only) MþF 33 1.01 (0.41e2.50) e ac (4)
(childhood and adult) MþF 81 1.21 (0.60e2.44) e ac (4)
(combined) MþF 105 1.18 (0.60e2.35)g,i No ac (4)
Hassan et al., 2007 USA Childhood, cohabitant or workplace (ever) MþF 294 1.02 (0.72e1.46)i e ac (7)
Lo et al., 2007 Egypt Cohabitant, exposed daily for 1 þ years (ever) MþF 41 6.0 (2.4e14.8)i e ac (2)
(continued on next page)
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Appendix Table 3 (continued )
Studyb Country Source (timing) of ETS exposure Sex Number
of casesc
RR (95% CI)d Dose
responsee
Adjustedf
Random effects meta-analysis based on 5 estimates (case control studies, including Lo et al.) 1.29 (0.61e2.70)x
Random effects meta-analysis based on 12 estimates (both study types, including Lo et al.) 1.16 (0.92e1.47)y
Random effects meta-analysis based on 11 estimates (both study types, excluding Lo et al.) 1.09 (0.94e1.28)z
All digestive cancers
Sandler et al., 1985b USA Mother (childhood) MþF 13 0.7 (0.1e5.6)g e u
Father (childhood) MþF 12 1.3 (0.4e4.2)g e u
Miller, 1990 USA Cohabitant (ever) or long-term
exposure outside home
F 29 10.8 (1.46e79.1)g,y e a
y Results relate to unemployed wives only, because no separation by ETS exposure for employed wives.
a Results are not included for seven studies (Curtin et al., 2009; Gerhardsson de Verdier et al., 1992; €Ogren et al., 1996; Slattery et al., 2003; Sun et al., 2010; Tranah et al.,
2011; Wang et al., 2006) as the analyses were not restricted to never smokers.
b Prospective studies are marked *. All other studies are case control.
c Number of cases: number among never smokers except where stated.
d RR (95% CI): estimated from data provided where necessary.
e Dose response: “-” indicates dose response not reported, “No” indicates dose response studied but no signiﬁcant trend seen, “d1”, “d2” ….“d6” indicate dose response
studied, signiﬁcant trend with more detailed data as follows: d1 RRs not speciﬁed but paper states “There are dose-response relations between total years of ETS exposure and
the risk of these three cancers.” (i.e. oesophagus, stomach and liver cancers). d2 RRs for gastric cardia cancer were 1.0, 3.5, 2.8, 5.8 for 0, 1e22, 23e42, 43 þ residential plus
occupational years exposed (trend p ¼ 0.03). RRs for distal gastric cancer showed no dose response (trend p ¼ 0.58). d3 RRs for distal gastric adenocarcinoma were 1.00, 1.15,
1.54 for no exposure, <12 or 12 person-years of exposure (trend p ¼ 0.03). RRs for distal gastric adenocarcinoma of 1.00, 1.38, 1.23 for no exposure, exposure to 1 or
2 þ smokers were also reported. RRs for gastric cardia adenocarcinoma showed no dose response (trend p ¼ 0.60). d4 RRs for stomach/cardia cancer were 1.00, 1.19, 0.34 for
never/seldom exposed, few times during week, daily exposure (trend p ¼ 0.05). Data from French and Italian centres only. d5 RRs were 1.00, 0.84, 1.15, 1.58 for no exposure,
<2 h/day, 2e7 h/day, >7 h/day exposure. P value not given but stated to be statistically signiﬁcant. d6 RRs were 1.00, 1.00, 2.09 for exposed never/seldom, few times during
week, daily (p for trend ¼ 0.03).
f Adjustment factors indicated by codes u, unadjusted; a, adjusted for age; c(n), adjusted for n confounding variables other than age (see Appendix Table 1).
g Estimated from data reported.
h Use of data for person-years of exposure instead of number of smokers in household made no material difference to the RR estimate.
i RR included in meta-analysis.
j Estimated from separate, non-independent estimates for gastric cardia cancer and distal gastric cancer. Use of data for person-years of exposure instead of years of
exposure (residential plus occupational) made no material difference to the RR estimate.
k Estimated from separate, non-independent estimates for gastric cardia adenocarcinoma and distal gastric adenocarcinoma.
l Estimated from separate, non-independent estimates for gastric cardia adenocarcinoma and distal gastric adenocarcinoma. Use of data for person-years of exposure
instead of number of smokers in household made no material difference to the RR estimate.
m Heterogeneity chisquared is 2.18 on 6 degrees of freedom (p ¼ 0.90). Egger test p ¼ 0.63.
n Heterogeneity chisquared is 10.24 on 5 degrees of freedom (p ¼ 0.07). Egger test p ¼ 0.54.
o Subjects exposed to ETS for >7 h/day.
p Heterogeneity chisquared is 9.77 on 6 degrees of freedom (p ¼ 0.13). Egger test p ¼ 0.58.
q Heterogeneity chisquared is 3.85 on 4 degrees of freedom (p ¼ 0.43). Egger test p ¼ 0.90.
r Compared to neither parent being a smoker.
s Compared to <5 years living with a smoker in adulthood.
t Compared to subjects who were never exposed to ETS from any source.
u Data came from Vrieling et al., 2010.
v Heterogeneity chisquared is 4.14 on 6 degrees of freedom (p ¼ 0.66). Egger test p ¼ 0.62.
w RR estimated by adding 0.5 to each cell as one cell had value of 0.
x Heterogeneity chisquared is 16.19 on 4 degrees of freedom (p ¼ 0.003). Egger test p ¼ 0.95.
y Heterogeneity chisquared is 20.38 on 11 degrees of freedom (p ¼ 0.04). Egger test p ¼ 0.92. Difference between study types p ¼ 0.82.
z Heterogeneity chisquared is 7.31 on 10 degrees of freedom (p ¼ 0.70). Egger test p ¼ 0.13.
Appendix Table 4
ETS exposure and cancer of the cervix in never smoking women.a
Studyb Country Source (timing) of ETS exposure Number of casesc RR (95% CI)d Dose responsee Adjustedf
Hirayama, 1987 * Japan Spouse (ever) 273 Not available No ac (1)
Butler, 1988 * USA Spouse (in marriage) 10 2.57 (0.70e9.44)g e ac (1)y
Jee et al., 1999 * Korea Spouse (ever) 203 0.90 (0.65e1.24)g,h No ac (5)
Nishino et al., 2001 * Japan Spouse (current) 11 1.10 (0.26e4.50)g e a
Trimble et al., 2005 * USA
1963 cohort Spouse (baseline) 81 2.0 (1.2e3.3)g ac (3)
Any cohabitant (baseline) 94 2.1 (1.3e3.3) ac (3)
Cohabitant but not spouse (baseline) 43 2.3 (1.1e4.9) ac (3)
1975 cohort Spouse (baseline) 49 1.6 (0.8e3.2)g e ac (2)
Any cohabitant (baseline) 55 1.4 (0.8e2.4) e ac (2)
Cohabitant but not spouse (baseline) 41 1.3 (0.6e3.2) e ac (2)
Chuang et al., 2011 * 10 European countries Childhood (ever) 87 1.05 (0.66e1.67)g No ac (14)
Random effects meta-analysis based on 6 estimates (prospective studies) 1.29 (0.92e1.82)i
Sandler et al., 1985a USA Spouse (ever) 56 2.1 (1.2e3.9)g e u
Sandler et al., 1985b Mother (childhood) 40 0.7 (0.2e2.5)h e u
Father (childhood) 34 1.7 (0.8e3.6)h e u
Slattery et al., 1989 USA Total (last 5 years) 81 1.7 (0.8e3.7)h d1 ac (3)
Cohabitant (last 5 years) 81 1.2 (0.7e2.2)g,h d2 ac (3)
Outside home (last 5 years) 81 1.6 (0.7e3.4)h No ac (3)
Coker et al., 1992 USA Spouse (ever) 36 0.9 (0.3e2.4)g,h e ac (5)
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Appendix Table 4 (continued )
Studyb Country Source (timing) of ETS exposure Number of casesc RR (95% CI)d Dose responsee Adjustedf
Cohabitant (ever) 36 0.9 (0.3e2.3)h e ac (5)
Co-worker (ever) 36 0.9 (0.3e2.3)h e ac (5)
Parent (ever) 36 0.3 (0.1e0.9)h e ac (5)
Hirose et al., 1996 Japan Spouse (current) 415 1.30 (1.07e1.59)g d3 ac (1)
Scholes et al., 1999 USA Cohabitant (current) 315 1.4 (1.0e2.0)g e ac (2)
Wu et al., 2003 Taiwan Cohabitant (adult) 89 2.73 (1.31e5.67)g d4 ac (4)
Co-worker (adult) 89 1.56 (0.83e2.92) No ac (4)
Cohabitant (childhood) 89 0.99 (0.54e1.83) No ac (4)
Co-worker (childhood) 89 1.03 (0.47e2.26) No ac (4)
Lifetime exposure (pack-years) 89 2.30 (0.91e5.84)h d5 ac (4)
Sobti et al., 2006 India Not speciﬁed 102 5.13 (2.54e10.4)g,h e u
Tsai et al., 2007 Taiwan Any source, 1þ cigarette-years (ever) 50 1.8 (0.9e4.1)g d6 ac (7)
Kordi Tamandani et al., 2008 India Spouse (ever) 198 1.97 (1.30e3.00)g,h e u
Shekari et al., 2012 Any (ever) 193 1.43 (1.09e1.88)h e ac (1)
Louie et al., 2011 Five countries Spouse (ever) 358 1.28 (0.88e1.85) No ac (10)
Spouse (current) 151 1.01 (0.56e1.83)g e ac (10)
Spouse (ex) 319 1.34 (0.91e1.96) e ac (10)
Abbas et al., 2014 India Not speciﬁed 187 2.31 (1.52e3.53)g,h,j e c (1)
Random effects meta-analysis based on 11 estimates (non-prospective studies, including Sobti
et al.)
1.73 (1.35e2.20)k
Random effects meta-analysis based on 17 estimates (both study types, including Sobti et al.) 1.58 (1.29e1.93)l
Random effects meta-analysis based on 16 estimates (both study types, excluding Sobti et al.) 1.48 (1.24e1.76)m
Random effects meta-analysis based on 5 estimates adjusting for sexual activity/HPV infection 1.29 (1.01e1.65)n
a Results are not included for 10 studies (Brown et al., 1982; Buckley et al., 1981; Coker et al., 2002; Hellberg et al., 1983; Lee et al., 2015a; Settheetham-Ishida et al., 2004;
Sull et al., 2004; Tajima et al., 1990; Tay and Tay, 2004; Zunzunegui et al., 1986) as the analyses were not restricted to never smokers.
b Prospective studies are marked *. Scholes et al., 1999 is a cross-sectional study. All other studies are case control.
c Number of cases: number among never smokers except where stated.
d RR (95% CI): estimated from data provided where necessary.
e Dose response: “-“ indicates dose response not reported, “No” indicates dose response studied but no signiﬁcant trend seen, “d1”, “d2” …. “d6” indicate dose response
studied, signiﬁcant trend with more detailed data as follows: d1 RRs 1.00, 1.14, 1.57, 3.43 for 0, 0.1e0.9, 1.0e2.9 3.0 þ hours/day total ETS exposure (trend p ¼ 0.02). d2 RRs
1.00, 0.62, 2.66 for 0, 0.1e1.5, 1.6 þ hours/day ETS exposure at home (trend p ¼ 0.04). d3 RRs 1.00, 1.00, 1.55 for 0, <20, 20 þ cigs/day smoked by husband (estimated trend
p < 0.001). d4 RRs 1.00, 2.13, 3.97 for 0, 1e10, >10 cigs/day smoked at home (trend p ¼ 0.002). d5 RRs 1.00, 1.90, 2.99 for 0, 1e20, >21 pack-years ETS exposure (trend
p ¼ 0.02). d6 RRs 1.00, 1.3, 2.1, 7.2 for 0, 1e10, 11e20, >20 pack-years ETS exposure (estimated trend p ¼ 0.00003).
f Adjustment factors indicated by codes u, unadjusted; a, adjusted for age; c(n), adjusted for n confounding variables other than age (see Appendix Table 1); y, adjusted for
age and education. Butler, 1988 also gives RRs of 3.01(0.83e10.87) adjusted for age and age married and 2.58 (0.70e9.56) adjusted for age and spouse occupation.
g RR included in meta-analysis.
h Estimated from data reported.
i Heterogeneity chisquared is 9.25 on 5 degrees of freedom (p ¼ 0.10). Egger test p ¼ 0.24.
j An alternative estimate of 2.21 (1.46e3.34) was calculated adjusted for CYP1A1m2 genotype.
k Heterogeneity chisquared is 26.43 on 10 degrees of freedom (p ¼ 0.003). Egger test p ¼ 0.20. Difference between study types p ¼ 0.03.
l Heterogeneity chisquared is 40.42 on 16 degrees of freedom (p ¼ 0.0007). Egger test p ¼ 0.16.
m Heterogeneity chisquared is 27.77 on 15 degrees of freedom (p ¼ 0.02). Egger test p ¼ 0.29.
n Heterogeneity chisquared is 2.13 on 4 degrees of freedom (p ¼ 0.71). Egger test p ¼ 0.54.
Appendix Table 5
ETS exposure and cancer of the endometrium in never smoking women.
Studya Country Source (timing) of ETS exposure Number of casesb RR (95% CI)c Dose responsed Adjustede
Hirose et al., 1996 Japan Spouse (current) 125 1.09 (0.76e1.57)f No ac (1)
Nishino et al., 2001 * Japan Spouse (current) 13 1.30 (0.40e3.90)f e a
Al-Zoughool et al., 2007 * 6 European countries Cohabitant or co-worker (baseline) -g,h 1.31 (0.74e2.34)f e a
-g,i 0.85 (0.65e1.11)f e a
Yang et al., 2010 Poland Home (ever) 358 0.86 (0.63e1.17)f,j e ac (8)
Work (ever) 358 1.00 (0.75e1.34)j e ac (8)
Home and/or work (ever) 358 0.92 (0.65e1.29) No ac (8)
Chuang et al., 2011 * 10 European countries Childhood (ever) 396 0.80 (0.65e0.99)f No ac (14)
Random effects meta-analysis based on 6 estimates 0.88 (0.78e1.01)k
a Prospective studies are marked *. All other studies are case control.
b Number of cases: number among never smokers except where stated.
c RR (95% CI): estimated from data provided where necessary.
d Dose response: “-” indicates dose response not reported, “No” indicates dose response studied but no signiﬁcant trend seen.
e Adjustment factors indicated by codes u, unadjusted; a, adjusted for age; c(n), adjusted for n confounding variables other than age (see Appendix Table 1).
f RR included in meta-analysis.
g Unspeciﬁed.
h Pre-menopausal at baseline.
i Post-menopausal at baseline.
j Estimated from data reported.
k Heterogeneity chisquared is 4.49 on 5 degrees of freedom (p ¼ 0.48). Egger test p ¼ 0.04.
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Appendix Table 6
ETS exposure and cancer of the ovary in never smoking women.
Studya Country Source (timing) of ETS exposure Number of casesb RR (95% CI)c Dose responsed Adjustede
Hirayama, 1987 * Japan Spouse (ever) 54 Not available No c (1)
Nishino et al., 2001 * Japan Spouse (current) 15 1.70 (0.58e5.20)f e a
Goodman and Tung, 2003 USA Cohabitant (childhood) 351 0.98 (0.72e1.35)f e ac (6)
Baker et al., 2006 USA Total (current) 246 0.68 (0.47e0.99)f d1 ac (6)
Gram et al., 2008 * Norway, Sweden Cohabitant (baseline) 109 1.1 (0.7e1.6)f,g e ac (3)
Chuang et al., 2011 * 10 European countries Childhood (ever) 250 0.88 (0.68e1.14)f,h e ac (1)
Random effects meta-analysis based on 5 estimates 0.91 (0.76e1.09)i
a Prospective studies are marked *. All other studies are case control.
b Number of cases: number among never smokers except where stated.
c RR (95% CI): estimated from data provided where necessary.
d Dose response: “-” indicates dose response not reported; “No” indicates dose response studied but no signiﬁcant trend seen; “d1” indicates dose response studied,
signiﬁcant trend with more detailed data as follows: d1 RRs 1.00, 0.68, 0.54, 0.39 for 0, <2, 2e8, >8 h/day ETS exposure (trend p ¼ 0.04).
e Adjustment factors indicated by codes u, unadjusted; a, adjusted for age; c(n), adjusted for n confounding variables other than age (see Appendix Table 1).
f RR estimate included in meta-analyses.
g Results quoted are for all tumours. The study also reports results by type of tumour: invasive tumours RR 1.1 (0.7e1.7), borderline tumours RR 1.1 (0.5e2.7), serous
tumours RR 1.4 (0.8e2.3) and mucinous tumours RR 1.1 (0.4e3.0).
h Estimated from data reported.
i Heterogeneity chisquared is 4.68 on 4 degrees of freedom (p ¼ 0.32). Egger test p ¼ 0.40.
Appendix Table 7
ETS exposure and cancer of the kidney in never smokers.
Studya Country Source (timing) of ETS exposure Sex Number of casesb RR (95% CI)c Dose responsed Adjustede
Kreiger et al., 1993 Canada Cohabitant or co-worker (current) F 72 0.87 (0.50e1.49)f,g,h d1 ac (1)
M 47 1.09 (0.57e2.09)f,g,h No ac (1)
Hu et al., 2005 Canada Residential and/or occupational (ever) F 171 1.75 (0.99e3.08)f,h No ac (1)
M 89 2.55 (0.99e6.58)f,h d2 ac (6)
Theis et al., 2008 Home (ever) MþF 129 1.32 (0.76e2.29)f,h d3, d4 ac (3)
Work (ever) MþF 129 1.57 (0.96e2.59)f No ac (3)
Public/private (ever) MþF 128 1.53 (0.90e2.60)f,i No ac (4)
Home/work (ever) MþF 128 1.94 (1.07e3.52)f,j d5 ac (3)
Chuang et al., 2011 * 10 European countries Childhood (ever) MþF 109 1.41 (0.93e2.14)f,h e ac (1)
Random-effects meta-analysis based on 6 estimates 1.33 (1.04e1.70)k
a Prospective studies are marked *. All other studies are case control.
b Number of cases: number among never smokers except where stated.
c RR (95% CI): estimated from data provided where necessary.
d Dose response: “-” indicates dose response not reported, “No” indicates dose response studied but no signiﬁcant trend seen, “d1”, “d2”….“d6” indicates dose response
studied, signiﬁcant trend with more detailed data as follows: d1 RRs 1.0, 0.6, 1.7 for <3, 3e8, >8 h/day ETS exposure (trend p ¼ 0.03). d2 RRs 1.0, 1.5, 2.5, 3.9 for never, 1e22,
23e42 and  43 years exposure (sum of years residential exposure and years occupation exposure) (trend p ¼ 0.001). d3 RRs 1.00, 0.86, 2.18 for no exposure, 1e20 or >20
years exposure (trend p ¼ 0.010). d4 RRs 1.00, 0.83, 2.37 for no exposure, 1e29999 or 30000 þ hours exposure (trend p ¼ 0.008). d5 RRs 1.33, 1.92, 3.04 for 0e6569,
6570e24454, 24455e67707 or 67708 þ hours exposure (trend p ¼ 0.020).
e Adjustment factors indicated by codes a, adjusted for age; c(n),adjusted for n confounding variables other than age (see Appendix Table 1).
f Estimated from data reported.
g Compared to usual exposure of <3 h/day.
h RR included in meta-analysis.
i Compared to exposure of <1 h per week.
j Compared to 0e6569 h exposure.
k Heterogeneity chisquared is 5.47 on 5 degrees of freedom (p ¼ 0.36). Egger test p ¼ 0.52.
Appendix Table 8
ETS exposure and bladder cancer in never smokers.a
Studyb Country Source (timing) of ETS exposure Sex Number
of casesc
RR (95% CI)d Dose responsee Adjustedf
Hirayama, 1987 * Japan Spouse (ever) F 49 Not available Nog c (1)
Zeegers et al., 2002 * Netherlands Spouse (ever) MþF 48 0.89 (0.44e1.80)h,i e ac (1)
Parents (unspeciﬁedj) MþF 52 1.20 (0.56e2.40)h e ac (1)
Co-worker (unspeciﬁedj) MþF 40 1.40 (0.70e2.60)h e ac (1)
Cohabitant or co-worker (unspeciﬁedj) MþF 41 0.67 (0.36e1.25)h No ac (1)
Bjerregaard et al., 2006 * Three European countries Home and/or work (baseline) MþF 47 0.82 (0.46e1.48)i e ac (2)
Total (childhood) MþF 47 2.02 (0.94e4.35) e ac (2)
Alberg et al., 2007 * USA
1963 cohort Cohabitant (baseline) F 22 1.8 (0.8e4.5)i e ac (2)
Spouse only (unspeciﬁedj) F 15 1.1 (0.3e3.8)k e ac (2)
Other cohabitant only (unspeciﬁedj) F 18 3.0 (1.2e7.9)k e ac (2)
1975 cohort Cohabitant (baseline) F 23 0.9 (0.3e2.2)i e ac (2)
Spouse only (unspeciﬁedj) F 29 1.2 (0.4e3.6)k e ac (2)
Other cohabitant only (unspeciﬁedj) F 25 0.4 (0.1e3.3)k e ac (2)
Chuang et al., 2011 * 10 European countries Childhood (ever) MþF 90 1.01 (0.66e1.55)h,i e ac (1)
Random effects meta-analyses based on 5 estimates (prospective studies) 0.99 (0.75e1.31)l
Kabat et al., 1986 USA Spouse (ever) F 35 1.21 (0.54e2.69)h,i e u
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Appendix Table 8 (continued )
Studyb Country Source (timing) of ETS exposure Sex Number
of casesc
RR (95% CI)d Dose responsee Adjustedf
M 49 0.77 (0.38e1.55)h,i e u
Cohabitant (unspeciﬁedj) F 17 0.63 (0.18e2.18)h No u
M 23 1.49 (0.48e4.62)h No u
Co-worker or in transportation
(unspeciﬁedj)
F 17 2.51 (0.63e10.0)h No u
M 23 0.64 (0.23e1.75)h No u
Burch et al., 1989 Canada Cohabitant (ever) F 81 0.75 (0.33e1.71)i e ac (1)
M 61 0.94 (0.45e1.95)i e ac (1)
Co-worker (ever) F 81 0.93 (0.48e1.79) e ac (1)
M 61 0.97 (0.50e1.91) e ac (1)
Chen et al., 2005 Taiwan Any (unspeciﬁedj) F 6 1.09 (0.42e2.80)i e ac (4)
M 6 7.16 (1.87e27.4)i e ac (4)
Samanic et al., 2006 Spain Childhood (ever) F 105 0.67 (0.33e1.38)h No ac (3)
M 55 1.12 (0.60e2.10)h No ac (3)
Cohabitant (ever) F 106 1.38 (0.63e3.01)h,i,m No ac (3)
M 54 1.06 (0.56e2.00)h,i,m No ac (3)
Co-worker (ever) F 106 2.03 (1.07e3.87)h,n d1 ac (3)
M 55 0.37 (0.16e0.81)h,n Np ac (3)
Total (ever) MþF 161 0.7 (0.3e2.3) e
Jiang et al., 2007 USA Childhood (ever) F 41 1.64 (0.73e3.69)h d2 ac (3)
M 106 0.75 (0.46e1.21)h No ac (3)
Cohabitant (ever) F 42 1.33 (0.61e2.90)h,i No ac (3)
M 106 0.73 (0.45e1.19)h,i No ac (3)
Co-worker (ever) F 40 1.39 (0.65e2.97)h No ac (3)
M 98 0.89 (0.54e1.47)h No ac (3)
Social (ever) F 42 0.88 (0.39e2.00)h No ac (3)
M 106 1.14 (0.68e1.91)h No ac (3)
Total (ever) F 42 4.24 (0.90e20.04)h d3 ac (3)
M 106 1.15 (0.56e2.38)h No ac (3)
Baris et al., 2009 USA Childhood (ever) MþF 145 1.10 (0.72e1.68)h No ac (4)
Cohabitant (ever) MþF 145 1.09 (0.67e1.77)h,i No ac (4)
Co-worker (ever) MþF 145 1.18 (0.80e1.74)h No ac (4)
Total (ever) MþF 145 1.06 (0.52e2.14)h No ac (4)
Tao et al., 2010 China Childhood (ever) M 60 1.13 (0.55e2.30)h,o No ac (3)
F 58 1.83 (0.79e4.24)h,o d4 ac (3)
Spouse (ever) M 24 0.47 (0.08e2.59)h,i,o No ac (3)
F 61 1.84 (0.80e4.25)h,i,o No ac (3)
Other cohabitant (ever) M 50 1.38 (0.63e3.00)o No ac (3)
F 40 1.83 (0.72e4.67)o No ac (3)
Co-worker (ever) M 70 1.05 (0.51e2.14)o No ac (3)
F 36 1.65 (0.50e5.39)o No ac (3)
Total (ever) M 98 1.21 (0.63e2.32)o No ac (3)
F 97 1.83 (0.82e4.05)o No ac (3)
Zheng et al., 2012 Egypt Home (ever) M 212 1.41 (0.90e2.20)h,i e ac (5)
F 337 1.11 (0.82e1.50)h,i e ac (6)
Outside home (ever) M 212 1.30 (0.89e1.90)h e ac (5)
F 337 1.40 (0.89e1.22)h e ac (6)
Total (ever) M 212 1.49 (0.98e2.25)h e ac (5)
F 337 1.08 (0.80e1.47)h e ac (6)
Ferreccio et al., 2013 Chile Any (ever) MþF 65 1.25 (0.64e2.42)h,i e ac (3)
Wu et al., 2013 Taiwan Any (ever) MþF (261)p 1.78 (1.14e2.80)h,i,q e ac (4)
Random effects meta-analyses based on 17 estimates (case control studies) 1.17 (0.99e1.39)r
Random effects meta-analyses based on 22 estimates (both study types) 1.13 (0.98e1.30)s
a Results are not included for one study (Airoldi et al., 2005) as the analyses were not restricted to never smokers.
b Prospective studies are marked *. All other studies are case control.
c Number of cases: number among never smokers except where stated.
d RR (95% CI): estimated from data provided where necessary.
e Dose response: “-” indicates dose response not reported, “No” indicates dose response studied but no signiﬁcant trend seen; “d1”, “d2”….….“d4” indicates dose response
studied, signiﬁcant trend with more detailed data as follows: d1 RRs 1.0, 1.7, 1.7, 3.3 for 0, >0e135, >135e240 or >240 smoker-years occupational exposure (trend p ¼ 0.03).
d2 RRs 1.00, 0.99, 3.08 for no childhood exposure, exposure to 1 smoker or exposure to 2þ smokers (trend p ¼ 0.02). d3 RRs 1.00, 3.34, 5.48 for no exposure, intermediate
exposure or high exposure using an index of exposure over all the sources studied (trend p ¼ 0.03). d4 RRs 1.00, 1.54, 6.87 for no exposure from any source, smoking by 1
parent (estimated trend p ¼ 0.02).
f Adjustment factors indicated by codes u, unadjusted; a, adjusted for age; c(n), adjusted for n confounding variables other than age (see Appendix Table 1).
g Data are for cancer of the urinary organs.
h Estimated from data reported.
i RR included in meta-analysis.
j The source paper does not make clear the time period the ETS exposure relates to.
k Subjects with exposure from both their spouse and other cohabitants were not reported except for a note that this category did not contain any bladder cancers.
l Heterogeneity chisquared is 2.37 on 4 degrees of freedom (p ¼ 0.67). Egger test p ¼ 0.66.
m The authors give results for the sexes separately and combined. The result for the sexes combined (RR 2.1, 95% CI 0.5e8.8) is clearly inconsistent with the data provided for
the separate sexes.
n The authors give results for the sexes separately and combined. The result for the sexes combined (RR 0.7, 95% CI 0.2e2.4) is somewhat inconsistent with the data provided
for the separate sexes.
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o Compared to subjects who were unexposed to ETS from any source.
p Number of cases in never smokers not known; number given is total for study and includes cancers in smokers.
q Conﬁdence interval based on approximate calculation so may be unreliable.
r Heterogeneity chisquared is 20.28 on 16 degrees of freedom (p ¼ 0.21). Egger test p ¼ 0.74. Difference between study types p ¼ 0.31.
s Heterogeneity chisquared is 23.66 on 21 degrees of freedom (p ¼ 0.31). Egger test p ¼ 0.69.
Appendix Table 9
ETS exposure and brain cancer in never smokers.
Studya Country Source (timing) of ETS exposure Sex Number of casesb RR (95% CI)c Dose responsed Adjustede
Sandler et al., 1985b USA Mother (childhood) MþF 11 0.9 (0.1e7.3)f e u
Father (childhood) MþF 9 1.7 (0.4e6.5) e u
Hirayama, 1985 * Japan Spouse (ever) F 34 2.93 (0.82e10.5)f,g d1 c (1)
Ryan et al., 1992 Australia Spouse/partner (ever) F (98)h 1.61 (0.82e3.17)f,g,i e a
M (72)h 2.21 (0.58e8.36)f,g,i e a
Hurley et al., 1996 Australia Cohabitant (adulthood) MþF 172G 0.97 (0.61e1.53)f e ac (2)
Blowers et al., 1997 USA Spouse (ever) F (94G)h 0.7 (0.4e1.4)f e u
Parent (ever) F (94G)h 1.7 (0.8e3.7) e u
Johnson et al., 1999 Canada Cohabitant or co-worker (ever) F (210)h 1.96 (0.99e3.9)f d2 n
M (339)h 0.97 (0.5e1.7)f No n
Phillips et al., 2005 USA Spouse (10þ years earlier) MþF 95M 2.0 (1.1e3.5)f d3 ac (2)
Cohabitant, not spouse
(10þ years earlier)
MþF 95M 0.7 (0.4e1.1) No ac 92)
Co-worker (10þ years earlier) MþF 95M 0.7 (0.4e1.2) No ac (2)
Chuang et al., 2011 * 10 European countries Childhood (ever) MþF 193 1.05 (0.76e1.44)f d4 ac (10)
Random effects meta-analysis based on 10 estimates 1.25 (0.97e1.60)j
a Prospective studies are marked *. All other studies are case control.
b Number of cases: number among never smokers G ¼ glioma M ¼ meningioma.
c RR (95% CI): estimated from data provided where necessary.
d Dose response: “-” indicates dose response not reported, “No” indicates dose response studied but no signiﬁcant trend seen, “d1”, “d2”….“d4” indicates dose response
studied, signiﬁcant trend with more detailed data as follows: d1 RRs 1.00, 3.28, 4.92 for husband nonsmoker, ex or 1e19/day and 20þ/day (trend p¼ 0.002). d2 RRs 1.00, 1.42,
2.20, 2.67 for 0, 1e24, 25e45 and 46þ years of ETS exposure (trend p¼ 0.001). d3 RRs 1.0, 1.4, 2.3, 2.7 for 0, <13, 13e28, >28 years exposure to spousal ETS (trend p¼ 0.02). d4
RRs 1.00, 1.98, 1.71 for exposure never/seldom, few times during week, daily (trend p ¼ 0.05).
e Adjustment factors indicated by u, unadjusted; a, adjusted for age, c(n), adjusted for n confounding variables other than age (see Appendix Table 1); n, not knownwhether
estimate adjusted for confounding variables or not.
f RR estimate included in meta-analyses.
g Estimated from data reported.
h Numbers of cases in never smokers not known e number given (in brackets) is total for study and includes cancers in smokers.
i Estimated from separate, non-independent estimates for glioma and meningioma.
j Heterogeneity chisquared is 13.24 on 9 degrees of freedom (p ¼ 0.15). Egger test p ¼ 0.22.
Appendix Table 10
ETS exposure and lymphoma in never smokers.
Studya Country Source (timing) of ETS exposure Sex Number of casesb RR (95% CI)c Dose responsed Adjustede
Hirayama, 1987 * Japan Spouse (ever) F 85 Not available e ac (1)
Chuang et al., 2011 * 10 European countries Childhood (ever) MþF 246 0.97 (0.74e1.28)f e ac (1)
Lu et al., 2011 * USA Childhood only (ever) F 178 1.07 (0.80e1.44)g,h e ac (2)
Adulthood only (ever) F 163 1.18 (0.86e1.61)g,h e ac (2)
Childhood and adulthood (ever) F 202 1.23 (0.93e1.63)g,h e ac (2)
Total (ever) F 371 1.15 (0.90e1.46)g,h d1,d2,d3 ac (2)
Diver et al., 2014 * USA Childhood (any) MþF 591 0.96 (0.79e1.16) No ac (10)
Adulthood (past) MþF 448 0.96 (0.79e1.17) e ac (10)
Adulthood (current) MþF 467 0.98 (0.80e1.19) No ac (10)
Adulthood (ever) MþF 763 0.97 (0.81e1.16) e ac (10)
Home (current) MþF 205 0.91 (0.66e1.25) e ac (10)
Outside home (current) MþF 441 0.99 (0.81e1.21) e ac (10)
Any (ever) M 377 0.90 (0.72e1.24) e ac (9)
F 507 1.00 (0.80e1.27) e ac (9)
a Prospective studies are marked *. All other studies are case control.
b Number of cases: number among never smokers except where stated.
c RR (95% CI: estimated from data provided where necessary).
d Dose response: “-” indicates dose response not reported, “No” indicates dose-response studied but no signiﬁcant trend seen, “d1”… “d3” indicates dose response studied,
signiﬁcant trendwithmore detailed data as follows: d1 RRs 1.0, 1.20, 1.24, 1.51 for5, 5.1e20, 20.1e40, >40 years ETS exposure (trend p¼ 0.03). d2 RRs 1.0, 1.39, 1.09, 1.75 for
overall intensity of ETS exposure 1.0, 1.1e2.0, 2.1e3.0, >3.0 (trend p ¼ 0.01). d3 RRs 1.0, 1.18, 1.15, 1.49 for intensity-years 5, 5.1e25, 25.1e50, >50 (trend p ¼ 0.03).
e Adjustment factors indicated by u, unadjusted; a, adjusted for age; c(n) adjusted for n confounding variables other than age (see Appendix Table 1).
f Estimated from data reported.
g Compared to subjects with no ETS exposure from any source.
h Results are for non-Hodgkin lymphoma.
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Appendix Table 11
ETS exposure and cancer of other sites in never smokers.a
Studyb Country Source (timing) of ETS exposure Sex Number of casesc RR (95% CI)d Dose responsee Adjustedf
Bone cancer
Sandler et al., 1985b USA Mother (childhood) MþF 19 1.0 (0.2e4.6)g e u
Father (childhood) MþF 20 0.6 (0.2e1.6)g e u
Hirayama, 1987 * Japan Spouse (ever) F 17 Not available No c (1)
Skin cancer
Hirayama, 1987 * Japan Spouse (ever) F 23 Not available No c (1)
Female genital cancer
Sandler et al., 1985b USA Mother (childhood) F 72 1.0 (0.4e2.4)g e u
Father (childhood) F 59 1.3 (0.7e2.4)g e u
Endocrine gland cancer
Sandler et al., 1985a USA Spouse (ever) MþF 13 4.4 (1.2e17.4) e u
Sandler et al., 1985b USA Mother (childhood) MþF 11 1.9 (0.4e9.3)g e u
Father (childhood) MþF 11 1.6 (0.5e5.4)g e u
Prostate cancer
Chuang et al., 2011 * 10 European countries Childhood (ever) MþF 311 0.79 (0.62e0.99)g e ac (1)
Thyroid cancer
Chuang et al., 2011 * 10 European countries Childhood (ever) MþF 176 0.88 (0.64e1.19)g e ac (1)
Leukaemia
Hirayama, 1987 * Japan Spouse (ever) F 51 Not available No c (1)
Kasim et al., 2005 Canada Cohabitant (ever) MþF 266 0.99 (0.69e1.42)g d1 ac (4)
Co-worker (ever) MþF 244 1.20 (0.88e1.64)g d2 ac (4)
All haematopoietic cancer
Sandler et al., 1985b USA Mother (childhood) MþF 19 2.3 (0.7e7.5)g e u
MþF 17 2.4 (0.9e6.7)g e u
a Results are not included for ﬁve studies (Airoldi et al., 2005; Glaser et al., 2004; Kaijser et al., 2003; McGlynn et al., 2006; Paoff et al., 1995) as the analyses were not
restricted to never smokers.
b Prospective studies are marked *. All other studies are case control.
c Number of cases: number among never smokers unless indicated otherwise.
d RR (95% CI): estimated from data provided where necessary.
e Dose response: “-” indicates dose response not reported, “No” indicates dose response studied but no signiﬁcant trend seen, “d1”, “d2” indicates dose response studied,
signiﬁcant trend with more detailed data as follows: d1 RRs 1.00, 0.68, 0.98, 1.32 for never, <22, 22e39 and >39 years exposure (trend p¼ 0.004). d2 RRs 1.00, 0.98, 1.26, 1.57
for never, <15, 15e21 and >21 years exposure (trend p ¼ 0.001).
f Adjustment factors indicated by u, unadjusted; a, adjusted for age; c(n) adjusted for n confounding variables other than age (see Appendix Table 1 for further details).
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ETS exposure and total cancer incidence in never smokers.a
Studyb Country Source (timing) of ETS exposure Sex Number
of casesc
RR (95% CI)d Dose
responsee
Adjustedf
Total cancer (including lung cancer)
Hirayama, 1984a * Japan Spouse (ever) F 2705 1.14 (1.04e1.25)g,h d1 c (2)
Reynolds et al., 1987 * USA Spouse (ever) F 73 1.68 (1.04e2.71)g,h d3 ac (1)
Butler, 1988 * USA Spouse (in marriage) F 321 1.20 (0.94e1.54)h e a
Sandler et al., 1989 * USA Cohabitant (ever) F 501 1.00 (0.82e1.21)h e ac (3)
M 115 1.01 (0.66e1.53)h e ac (3)
Nishino et al., 2001 * Japan Spouse (current) F 426 1.10 (0.92e1.40)h e a
Chuang et al., 2011 * 10 European countries Childhood (ever) MþF 7808 0.97 (0.92e1.02)h No ac (10)
He et al., 2012 * China Home/work (ever) M 44 1.77 (0.88e3.60)h d5 ac (8)
F 25 1.26 (0.49e3.19)h d5 ac (8)
Home only (ever) MþF 30 2.16 (1.01e4.64) e ac (9)
Work only (ever) MþF 38 1.66 (0.86e3.22) e ac (9)
Batty et al., 2014 * UK Total (current) M 14 2.06 (0.48e8.76)g,h,i No ac (4)
F 40 0.74 (0.38e1.44)g,h,j No ac (4)
Random effects meta-analysis based on 11 estimates (prospective studies) 1.09 (0.98e1.20)k
Miller, 1984 USA Spouse (ever) F 123 0.95 (0.57e1.60)g,h e a
Sandler et al., 1985a USA Spouse (ever) F 192 1.96 (1.30e2.97)g,h,l e a
M 39 1.53 (0.41e5.68)g,h,l e u
Sandler et al., 1985c Cohabitant (ever) MþF 157 1.78 (1.09e2.91)g,l d2 u
Sandler et al., 1985b Mother (childhood) MþF 191 1.2 (0.7e2.2)g e u
Father (childhood) MþF 173 1.2 (0.8e1.8)g e u
Miller, 1990 USA Cohabitant (ever) or long-term
exposure outside home
F 82 6.40 (2.34e17.5)g,h,m e a
Iribarren et al., 2001 USA Cohabitant (current) F 1220 0.94 (0.82e1.08)h No ac (10)
M 239 0.93 (0.65e1.31)h No ac (10)
Total (current) F 1220 0.95 (0.84e1.08) No ac (10)
M 239 1.28 (0.94e1.75) No ac (10)
McGhee et al., 2005 Hong Kong Cohabitants (10 years earlier) F 764 1.35 (1.03e1.76)h e ac (1)
M 851 1.16 (0.85e1.60)h e ac (1)
(continued on next page)
Appendix Table 12 (continued )
Studyb Country Source (timing) of ETS exposure Sex Number
of casesc
RR (95% CI)d Dose
responsee
Adjustedf
MþF 1615 e d4 ac (1)
Random effects meta-analysis based on 8 estimates (non-prospective studies, including Miller,
1990)
1.28 (0.98e1.66)n
Random effects meta-analysis based on 19 estimates (both study types, including Miller,
1990)
1.13 (1.03e1.25)o
Random effects meta-analysis based on 18 estimates (both study types, excluding Miller,
1990)
1.10 (1.01e1.20)p
Smoking-related cancer (including lung cancer)
Sandler et al., 1985b USA Mother (childhood) MþF 47 0.8 (0.3e2.4)g,h e u
Father (childhood) MþF 41 1.7 (0.9e3.3)g,h e u
Reynolds et al., 1987 * USA Spouse (ever) F <73 7.01 (0.73e67.5)g,h d6 ac (1)
Butler, 1988 * USA Spouse (in marriage) F 41 1.22 (0.61e2.44)h e a
Sandler et al., 1989 * USA Cohabitant (ever) F 76 1.45 (0.88e2.40)h e ac (3)
M 32 0.96 (0.43e2.16)h e ac (3)
Nishino et al., 2001 * Japan Spouse (current) F 56 1.70 (0.94e2.90)h e a
Chuang et al., 2011 * 10 European countries Childhood (ever) MþF 619 1.00 (0.84e1.20)h No ac (10)
Random effects meta-analysis based on 8 estimates 1.23 (0.97e1.55)q
Smoking-related cancer (excluding lung cancer)
Butler, 1988 * USA Spouse (in marriage) F 33 1.06 (0.47e2.36) e a
Cancer other than lung cancer
Gillis et al., 1984 * Scotland Cohabitant (current) F 43 1.26 (0.62e2.56) e a
M 8 0.50 (0.10e2.48) e a
Hill et al., 2007 * New Zealand
1981e84 cohort Cohabitant (baseline) F z1285 1.04 (0.90e1.21) e ac (8)
M z548 1.19 (0.95e1.49) e ac (8)
1996e99 cohort Cohabitant (baseline) F z1693 1.21 (1.05e1.40) e ac (8)
M z1070 0.98 (0.80e1.20) e ac (8)
Cancer other than smoking-related
Sandler et al., 1985b USA Mother (childhood) F 144 1.3 (0.7e2.5)g e U
Father (childhood) M 132 1.1 (0.7e1.7)g e U
Sandler et al., 1989 * USA Cohabitant (ever) F 425 0.93 (0.76e1.54) e ac (3)
M 83 1.03 (0.40e2.62) e ac (3)
Chuang et al., 2011 * 10 European countries Childhood (ever) MþF 7189 0.97 (0.92e1.01) d7 ac (10)
a Results are not included for one study (Eng et al., 2015) as the analysis was not restricted to never smokers.
b Prospective studies are marked *. Iribarren et al., 2001 is a cross-sectional study. All other studies are case control.
c Number of cases: number among never smokers.
d RR (95% CI): estimated from data provided where necessary.
e Dose response: “-” indicates dose response not reported; “No” indicates dose response studied but no signiﬁcant trend seen; “d1”, “d2”… “d7” indicates dose response
studied, signiﬁcant trend with more detailed data as follows: d1 RRs 1.00, 1.12, 1.23 for husband nonsmoker, ex-smoker or 1e19/day, 20þ/day (one-tailed trend p ¼ 0.0002).
d2 RRs 1.0, 1.5, 2.3, 2.8 for 0, 1, 2, 3þ cohabitants smoking (trend p < 0.01). d3 signiﬁcant trend (p ¼ 0.04) was noted with pack-years ETS exposure but RRs by level were not
given. d4 RRs 1.0, 1.14, 1.74 for 0, 1 and 2þ smoking cohabitants (sexes combined), trend p ¼ 0.003. d5 RRs of 1.0, 1.51, 1.50, 3.70 for exposure score 0, 1e2, 3e4, 5e6 for both
sexes combined, trend p¼ 0.019. Combined exposure score based on exposure at home (cigarettes per day: 0¼ no exposure, 1¼ <4 pack-years, 2¼ 4 to <8 pack-years, 3¼ 8þ
pack-years) and exposure at work ((cigarettes per day x years x smokers x hours/day)/100: 0¼ no exposure, 1¼ <5, 2¼ 5 to <15, 3¼ 15þ). d6 A signiﬁcant trend (p¼ 0.0007)
was noted with pack-years ETS exposure but RRs by level were not given. d7 RRs 1.0, 1.01, 1.08 for ETS exposure never/seldom, few times during week, daily (trend p¼ 0.08).
f Adjustment factors indicated by u, unadjusted; a, adjusted for age; c(n), adjusted for n confounding variables other than age (see Appendix Table 1 for further details).
g Estimated from data reported.
h RR included in meta-analyses.
i Based on analysis of ETS exposure as measured by salivary cotinine. Analysis based on self-reported ETS exposure gave RR of 1.79 (0.45e7.18).
j Based on analysis of ETS exposure as measured by salivary cotinine. Analysis based on self-reported ETS exposure gave RR of 0.75 (0.29e1.93).
k Heterogeneity chisquared is 19.97 on 10 degrees of freedom (p ¼ 0.03). Egger test p ¼ 0.08.
l There were a total of two never smokers with lung cancer but it was not stated how many there were in each sex or how many provided full data on smoking by
cohabitants.
m Results relate to unemployed wives only because no separation by ETS exposure for employed wives.
n Heterogeneity chisquared is 27.98 on 7 degrees of freedom (p ¼ 0.0002). Egger test p ¼ 0.07. Difference between study types p ¼ 0.30.
o Heterogeneity chisquared is 49.01 on 18 degrees of freedom (p ¼ 0.0001). Egger test p ¼ 0.01.
p Heterogeneity chisquared is 36.33 on 17 degrees of freedom (p ¼ 0.004). Egger test p ¼ 0.03.
q Heterogeneity chisquared is 9.38 on 7 degrees of freedom (p ¼ 0.23). Egger test p ¼ 0.09.
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